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Atopic dermatitis 
Atopic dermatitis (AD) or atopic eczema , is a chronic inflammatory skin disease 
characterized by dry skin, itching and recurrent red and scaly skin lesions. It is a relatively 
common skin disease with an estimated prevalence of 10-20%.1 The majority of patients 
show their first clinical symptoms in infancy or early childhood, with reported percentages 
of 60% before the age of 1 year and 85% before the age of 5 year.2  
The pathogenesis of AD is characterized by a complex interaction between a genetic 
background and different environmental factors.3,4 Over the last years genome wide 
linkage mapping as well as selective region specific linkage mapping based on candidate 
genes, has revealed many possible AD related loci on different chromosomes.5 Summarizing 
there seem to be two major groups of genes present within the genetic background of AD: 
genes encoding for epidermal or other epithelial structural proteins and genes encoding for 
major elements of the immune system. 4,5  
The term “atopic dermatitis” was coined by Wise and Sulzberger in 1933 and reflects 
the association between AD and other so-called atopic disorders, such as asthma and 
allergic rhinitis.6 The diagnose is based on clinical criteria, with the extensive criteria of 
Hanifin and Raijka as the classical starting point published in 1980.7 In the years to follow 
several modifications were proposed, leading to publications on different new sets of 
criteria.8 For our own research purposes we currently use the diagnostic criteria 
formulated by the UK working party on AD, which have been extensively validated in the 
past and are widely accepted as a diagnostic tool (figure 1).8,9  
 
 
 
Must have 
• An itchy skin condition (or report of scratching or rubbing in a child 
 
Plus three or more of the following 
• History of itchiness in skin creases such as folds of the elbows, behind the 
knees, fronts of ankles, or around neck (or the cheeks in children under 4 years) 
• History of asthma or hay fever (or history of atopic disease in a first degree 
relative in children under 4 years 
• General dry skin in the past year 
• Visible flexural eczema (or eczema affecting the cheeks or forehead and outer 
limbs in children under 4 years) 
• Onset in the first two years of life (not always diagnostic in children under 4 
years) 
 
Figure 1. The diagnostic criteria for AD as described by the UK working party on AD 
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The term atopy itself is used to describe the genetic predisposition to become IgE –
sensitized to allergens commonly occurring in the environment.10 This sensitization can be 
detected by performing skin prick tests (SPT) or measuring serum specific IgE against 
common aero-or food allergens. Whether or not the presence of this sensitization should 
be a mandatory criterium for the diagnosis of AD is still debated.11 This controversy is 
nicely illustrated by a question phrased by Hywell Williams: “How atopic is atopic 
dermatitis?”.12 His conclusion was that it would be premature to divide patients with AD 
based on sensitization alone, which still seems valid today. The role of IgE in the 
pathogenesis of AD may indeed not be that of a major causative factor but only that of a 
very common epiphenomenon.12 
 
 
Assessment of disease severity 
Disease severity would ideally be assessed using a disease specific and objective 
laboratory marker. Unfortunately such a laboratory test is currently not available for 
assessment of disease severity in AD. The commonly used “next best thing” are scoring 
systems based on the objective and/or subjective clinical features of AD. “Objective” In 
this context means scored by a physician and “subjective” means scored directly by the 
patient or caregiver. Of course the so-called “objective” features still include a certain 
degree of subjectivity, because the physician has to score them based on his personal 
observations. In a recently performed review on behalf of the European Dermato-
Epidemiology Network, the authors were able to identify 20 different scoring systems used 
to measure disease severity in AD.13 They concluded that only three out of these 20 had 
been validated adequately enough to recommend their use in clinical trials and daily 
clinical practice. One of these three was the Patient-Oriented Eczema Measure (POEM), 
which is a subjective, questionnaire based system. The other two were the more objective 
Eczema Area and Severity Index (EASI) and the SCORing AD (SCORAD) index, including its 
derivative the so-called objective SCORAD.13  As the objective SCORAD was used in the 
studies described in this thesis, the SCORAD index and the objective SCORAD will be 
outlined in more detail in the paragraph below.  
In the original publication on behalf of the European Taskforce on Atopic Dermatitis 
(ETFAD) the SCORAD is described as an index incorporating the extent of the disease 
according to the rule of nines (A, 20%), together with the intensity of six clinical features 
on a scale of 0-3 (B, 60%) and the two subjective symptoms itch and sleeplessness on a 
scale of 0-10 (C, 20%).14,15 The score is achieved by using the formula A/5 + 7B/2 + C, 
leading to a maximum score of 103 (figure 2). Although subjective symptoms yield very 
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important information from a patient’s perspective, they are probably not the best choice 
to monitor disease activity in clinical trails, as they may be biased by the social or cultural 
background of patients and caregivers.16 This is why the ETFAD recommends using the 
objective SCORAD, instead of the original SCORAD index, in determining disease severity in 
clinical trials.16 In the objective SCORAD the subjective symptoms are excluded, leading to 
the formula A/5 + 7B/2, with a maximum score of 83. An additional 10 points may be 
added in patients with severely disfiguring lesions on the face or hands.16 
  
 
Figure 2.  Assessment of disease severity in AD using the SCORAD index (A/5+7B/2+C) or objective 
SCORAD (A/5+7B/2). 
 
Diagnostic work-up  
As discussed previously the diagnosis of AD is based on criteria, which are obtained by 
a correct medical history and physical examination. Skin biopsies are not routinely used to 
substantiate the eczematous nature of the skin lesions in AD, although the histology of 
acute as well as chronic skin lesions is well established. The diagnostic work-up is primarily 
aimed at identifying environmental factors that may worsen the skin disease in individual 
patients. Non-specific factors, such as irritative substances and stress, can be identified by 
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including specific questions in the medical history or by using standardized questionnaires. 
The more specific factors include different food-, aero- and contact allergens that may 
cause relevant allergic reactions in patients with AD. Indications for an allergologic work-
up include severe and/or refractory skin disease as well as reported flare-ups of skin 
lesions after contact with suspected allergens. Sensitization against aero- or food allergens 
is strongly associated with AD and can be readily detected in a large number of patients. 
However, great care must always  be taken to avoid confusion between a detectable 
sensitization and a clinically relevant allergy.  
 
Food allergens 
Clinically relevant food-allergies in AD are almost exclusively limited to a small sub-
population of relatively young children. These children may benefit from dietary 
measurements and need to be separated from the majority of children with AD in whom 
diets are not beneficial. In the Netherlands the most commonly implicated food allergens 
include cow’s milk, hen’s egg and peanut.  
The allergologic work-up in children with AD and suspected food allergy starts with a 
careful history and clinical examination. Traditionally this is combined with the results 
from Skin Prick Tests (SPT) and/or the measurement of serum specific IgE. Both tests are 
aimed at detecting immediate type sensitization against the suspected food allergens. The 
Skin Application Food Test (SAFT) has been described as a reliable and child friendly 
alternative to the SPT in children with AD below the age of 3 years.17 The golden standard 
for the diagnosis of a food allergy is the double blind placebo controlled oral challenge 
(DBPCOC), followed by a supervised reintroduction period.18 Although DBPCOC are time-
consuming and carry a certain risk, they may be necessary in cases were serology, skin 
tests and history do not reveal a conclusive result. 
In recent years the Atopy Patch Test (APT) has been advocated as an useful addition 
to the allergologic work-up of children with AD and suspected food allergy. This skin test is 
aimed at detecting delayed type, eczematous skin reactions, following epicutaneous 
application of food (or aero-)allergens in patients with AD. The APT was first described in 
detail in 1982 and has been the focus of increased research interest over the last 10-15 
years.19 Combining the results from the APT with results from traditional tests has been 
reported to reduce the number of OC necessary in order to reach a conclusive result 
regarding relevant food allergies.20,21 Although in theory the combination of a skin test 
aimed at immediate type allergic reactions (IgE, SPT or SAFT) and a skin test aimed at 
delayed type allergic reactions (APT) seems promising, there have been conflicting results 
published regarding the additional value of the APT in daily clinical practice.20-26  
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Aero allergens 
Traditional tests used to detect sensitization against aeroallergens include SPT, 
Intracutaneous Tests (IT) and measurement of serum specific IgE. The relevance of a 
sensitization with aero allergens in patients with AD remains controversial as there is 
currently no gold standard available for confirmation of this relevance. However, there 
does seem to be a subgroup of patients with AD where contact with aeroallergens, such as 
house dust mite or grass pollen, is capable of worsening eczematous skin lesions.27 
Adequate avoidance measures may be helpful in controlling AD in these patients, although 
results from clinical trails are contra dictionary.28-30   
Additional evidence for a possible role of aeroallergens in the pathogenesis of AD is 
found in the fact that epicutaneous application of these allergens via the APT can elicit 
eczematous skin reactions in patients with AD.31 Differences in methodology and the 
previously mentioned lack of a golden standard for a relevant sensitization are two major 
obstacles in the development of the APT as an addition to our allergologic work-up in 
patients with AD.19,32 Most of the current clinical data on the APT with aeroallergens is 
based on adult patient populations and pediatric data is scarce.  
 
Contact allergens 
Although patients with AD are not more likely to become sensitized against common 
contact allergens than the general population, this possibility should be kept in mind in 
patients with severe and/or refractory skin disease.33 Relevant contact allergies are more 
frequent in adolescence and adulthood but may also occur in childhood.34 Patch tests can 
be used to confirm a sensitization against contact allergens, such as ingredients in over the 
counter skin care products or topical medication. 
 
 
Disease management 
The treatment of AD is aimed at restoring the epidermal barrier defect and reducing 
skin inflammation. Emphasis has to be put on the proper use of topical medication as well 
as avoidance of the different environmental factors that may negatively influence disease 
severity. Several educational programs have been shown to be an effective addition to the 
treatment of patients with AD, reducing severity of skin disease and improving quality of 
life.35 A short overview of the currently available treatment options is listed below. 
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First line treatment 
In most patients with uncomplicated mild to moderate AD, disease control can be 
obtained by use of emollients and once daily applications of topical corticosteroids if 
necessary.36 Emollients are used to alleviate skin dryness and restore part of the defective 
epidermal barrier. Whether or not emollients based on the lipid composition of the human 
stratum corneum have a superior effect compared to more conventional emollients 
remains to be established.37 Research in this field seems promising, especially in light of 
recent advances in our knowledge on epidermal barrier defects in patients with AD.38 
Topical corticosteroids are available in different potencies, which correlate with 
their risk for local and systemic side effects.39 The appropriate potency for an individual 
patient has to be established based on the age of the patient and the sensitivity to possible 
corticosteroid side effects of the body area which is to be treated.39 In a long term 
maintenance treatment, intermittent use of once daily topical corticosteroids (2-4 days 
per week) has been shown to reduce the number of eczematous flare-ups.40  
 
Topical alternatives 
An alternative to topical corticosteroids became recently available after the 
discovery of topical calcineurine inhibitors.41 These molecules function as topical 
immunosuppressants by selectively blocking T-cell activation and proliferation. Currently 
both pimecrolimus (Elidel®) and tacrolimus (Protopic®) are registered for use in patients 
with AD above the age of two years. The first is available as an 1% ointment, whereas the 
latter is available as an 0.03% and 0.1% ointment. Efficacy and safety studies look very 
promising, although both products are not more effective than potent topical 
corticosteroids. Their unique safety profile makes them a valid treatment alternative, 
especially on body areas prone to corticosteroid side effects such as the face and body 
folds.41 Possible long term side effects remain to be further clarified in the future. 
Topical coal tar (TCT) preparations form another alternative or adjuvans to topical 
corticosteroids. They originate from the time before the discovery of topical 
corticosteroids more than fifty years ago. Their exact mode of action is unknown but they 
have anti-pruritic as well as anti-inflammatory properties, making them effective in the 
treatment of AD.42 Although much has been said about the possible carcinogenic nature of 
TCT, there has been no conclusive evidence of increased malignancies after dermatological 
use.42 However, data on increased levels of carcinogenic substances in urine samples of 
patients treated with TCT, together with their unpleasant odour and the increased risk of 
sun-burn and folliculitis limits their use in current clinical practice.43  
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Intervention treatment 
Patients with severe and/or refractory AD may need a different therapeutic 
approach. Well known intervention treatments include systemic corticosteroids, 
cyclosporine A, azathioprine or photo(chemo)therapy.36 All off these interventions have 
(relative) contraindications and potential side effects, limiting their use in children. Wet-
wrap treatment (WWT) with diluted topical corticosteroids has been advocated as a 
relatively safe and effective intervention treatment in children with severe and/or 
refractory AD.44  However, it is a laborious and time-consuming treatment, which calls for 
close supervision.[ ]  WWT should not be misused and has to be reserved as a short term 
intervention treatment in carefully selected patients.45  
 
Secondary skin infections 
Patients with AD are at risk for secondary skin infections, due to their disrupted 
epidermal barrier, combined with a suppression of their non-specific, innate immune system 
and a skewing of their specific immunity towards a so-called Th-2 response.4 The most 
frequent pathogens are bacteria (e.g. Staphylococcus aureus), but viral (e.g. Herpes 
Simplex) as well as yeast and fungal (e.g. Malazessia and Trichophyton species) infections 
may also occur. Additional antimicrobial treatment should be started when clinical signs of 
active skin infection are present. Mild bacterial infections may be treated with topical fucidic 
acid, which has been shown to be very effective against Staphylococcus aureus. More 
widespread infections should be treated with short courses of systemic antibiotics. 
Recolonization with Staphylococcus aureus will rapidly occur after cessation of topical or 
systemic antibiotics and maintenance treatment should be avoided as this may lead to skin 
colonization with resistant strands of bacteria. Widespread secondary Herpes simplex 
infections, also known as eczema herpeticum, can be a serious and possibly even life-
threatening complication in AD and should be treated by systemic antiviral agents such as 
acyclovir and others.  Secondary yeast and fungal infections may be treated using topical or 
systemic antimycotics. 
General introduction  16-134 
References 
1. Williams H, Robertson C, Stewart A, et al. Wolrdwide variations in the prevalence of 
symptoms of atopic eczema in the International Study of Asthma and Allergies in 
Childhood. J Allergy Clin Immunol 1999; 103:125-138 
2. Kay J Gawkrodger DJ, Mortimer MJ, et al. The prevalence of childhood atopic eczema 
in a general population. J Am Acad Dermatol 1994; 30:35-39 
3. Schultz Larsen F. Atopic dermatitis:a genetic-epidemiologic study in a population-
based twin sample. J Am Acad Dermatol 1993; 28:719-723 
4. Bieber T. Atopic dermatitis. N Engl J Med 2008; 358:1483-1494 
5. Morar N, Willis-Owen SAG, Moffat MF, et al The genetics of atopic dermatitis. J 
Allergy Clin Immunol 2006; 118:24-34 
6. Wise F, Schulzberger MB. Editorial remarks. In: Yearbook of Dermatology and 
Siphilology. Chicago: Yearbook Medical Publishers, 1933:59 
7. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 
(Stockh) 1980; Suppl. 92:44-47 
8. Brenninkmeijer EEA, Schram ME, Leeflang MMG, et al. Diagnostic criteria for atopic 
dermatitis: a systematic review. Br J Dermatol 2008; 158:754-765 
9. Williams HC, Burney PGJ, Hay RJ et. al. The U.K. working party’s diagnostic criteria 
for atopic dermatitis. 1. Derivation of a minimum set of discriminators for atopic 
dermatitis. Br J Dermatol. 1994; 131:383-396 
10. Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global 
use: report of the nomenclature review committee of the World Allergy Organization, 
october 2003. J Allergy Clin Immunol 2004; 113:832-836 
11. Bos JD, van Leent EJM, Sillevis Smitt JH. The millennium criteria for the diagnosis of 
atopic dermatitis. Exp. Dermatol 1998; 7:132-138 
12. Williams H, Flohr C. How epidemiology has challenged 3 prevailing concepts about 
atopic dermatitis. J Allergy Clin Immunol 2006; 118:209-213 
13. Schmitt J, Langan S, Williams HC. What are the best outcome measurements for 
atopic eczema? A systematic review. J Allergy Clin Immunol 2007; 120:1389-1398 
14. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the 
European Taskforce on Atopic Dermatitis. Dermatology 1993; 186(1):23-31 
15. Kunz B, Oranje AP, Labrèze L, et al. Clinical validation and guidelines for the SCORAD 
index: consensus report of the European Taskforce on Atopic Dermatitis. Dermatology 
1997; 195(1):10-19. 
16. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der Spek FB. Practical 
issues on the interpretation of scoring atopic dermatitis: the SCORAD index, objective 
SCORAD and the three-item severity score. Br J Dermatol 2007; 157:645-648 
17. De Waard-van der Spek FB, Elst EF, Mulder PG, et al. Diagnostic tests in children with 
atopic dermatitis and food allergy. Allergy 1998; 53(11):1087-1091 
18. Muraro MA. Diagnosis of food allergy: the oral provocation test. Pediatr Allergy 
Immunol 2001; 12 (suppl. 14):31-36 
19. Turjanmaa K, Darsow U, Niggeman B, et al. EAACI/GA2LEN position paper: present 
status of the atopy patch test. Allergy 2006; 61(12):1377-1384 
20. Isolauri E, Turjanmaa K. Combined skin prick and patch testing enhances 
identification of food allergy in infants with atopic dermatitis. J Allergy Clin Immunol 
1996; 97(1):9-15 
21. Roehr CC, Reibel S, Ziegert M et al. Atopy patch tests, together with determination 
of specific IgE levels, reduce the need for oral food challenges in children with atopic 
dermatitis. J Allergy Clin Immunol 2001; 107(3):548-553 
 
 
 
 
General introduction  17-134 
22. Majamaa H, Moisio P, Holm K et al. Cow’s milk allergy: diagnostic accuracy of skin 
prick and patch tests and specific IgE. Allergy 1999; 54:346-351 
23. Vanto T, Juntunen-Backman K, Kalimo K et al. The patch test, skin prick test and 
serum milk-specific IgE as diagnostic tools in cow’s milk allergy in infants. Allergy 
1999; 54:837-842 
24. Niggeman B, Reibel S, Wahn U. The atopy patch test (APT) – a useful tool for the 
diagnosis of food allergy in children with atopic dermatitis. Allergy 2000; 55:281-285 
25. Stromberg L. Diagnostic accuracy of the atopy patch test and the skin-prick test for 
the diagnosis of food allergy in young children with atopic eczema/dermatitis 
syndrome. Acta Paediatr 2002; 91:1044-1049 
26. Breuer K, Heratizadeh A, Wulf A, et al. Late eczematous reactions to food in children 
with atopic dermatitis. Clin Exp Allergy 2004; 34:817-824 
27. Tupker R, DeMonchy J, Coenraads P, et al. Induction of atopic dermatitis by 
inhalation of house dust mite. J Allergy Clin Immunol 1996; 97:1064-1070  
28. Tan B, Weald D, Strickland I, et al. Double-blind controlled trail of effect of house-
dust mite allergen avoidance on atopic dermatitis. Lancet 1996; 347:15-18 
29. Ricci G, Patrizi A, Specchia F, et al. Effect of house dust mite avoidance measures in 
children with atopic dermatitis. Br J Dermatol 2001; 144:912-913 
30. Oosting AJ, de Bruin-Weller MS, Terreehorst I, et al. Effect of mattress encasings on 
atopic dermatitis outcome measures in a double-blind, placebo-controlled study: the 
Dutch mite avoidance study. J Allergy Clin Immunol 2002; 110(3):500-506 
31. Ring J, Darsow U, Behrendt H. Role of aeroallergens in atopic eczema: proof of 
concept with the atopy patch test. J Am Acad Dermatol 200; 45:s49-s52 
32. Darsow U, Laifaoui J, Kerschenlohr K, et al. The prevalence of positive reactions in 
the atopy patch test with aeroallergens and food allergens in subjects with atopic 
eczema: a European multicenter study. Allergy 2004; 59:1318-1325 
33. Akhavan A, Cohen SR. The relationship between atopic dermatitis and contact 
dermatitis. Clin Dermatol 2003; 21:158-162 
34. Giodano-Labadie F, Rancé F, Pellegrin F, et al. Frequency of contact allergy in 
children with atopic dermatitis: results of a prospective study of 137 cases. Contact 
Dermatitis 1999; 40:192-195 
35. Staab D, Diepgen T, Fartasch M, et al. Age-related, structured education programmes 
improve the management of atopic dermatitis in children and adolescents. Results of 
the German Atopic Dermatitis Intervention Study (GADIS). BMJ 2006; 332:933-938 
36. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in 
children and adults: European Academy of Allergology and Clinical 
Immunology/American Academy of Allergy, Asthma and Immunology/Practall 
consensus report. J Allergy Clin Immunol 2006; 118:152-169 
37. Lodén M. The clinical benefit of moisturizers. JEADV 2005; 19:672-688 
38. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier 
dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin 
Immunol 2006; 118:3-21 
39. NVDV / kwaliteitsinstituut CBO. Richtlijn dermatocorticosteroiden, 2000. ISBN:90-
6910-232-3 
40. Berth-Jones J, Damstra RJ, Golsch S, et al. Twice weekly fluticasone propionate 
added to emollient maintenance treatment to reduce risk of relapse in atopic 
dermatitis: randomised, double blind, parallel group study. BMJ 2003; 326:1367-1373 
41. Ashcroft DM, Dimmock P, Garside R, et al. Efficacy and tolerability of topical 
pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of 
randomised controlled trails. BMJ 2005; 330(7490):516 
 
 
 
General introduction  18-134 
42. Roelofzen JH, Aben KK, van der Valk PG, et al. Coal tar in dermatology. J Dermatol 
Treat 2007; 18(6):329-334 
43. Veenhuis RT, van Horssen J, Bos RP, et al. Highly increased urinary 1-hydroxypyrene 
excretion rate in patients with atopic dermatitis treated with topical coal tar. Arch 
Dermatol Res 2002; 294(4):168-171 
44. Oranje AP, Devillers ACA, Kunz B et al. Treatment of patients with atopic dermatitis 
using wet-wrap dressings with diluted steroids and/or emollients. An expert panel’s 
opinion and review of the literature. J Eur Acad Dermatol Venereol. 2006; 
20(10):1277-1286 
45. Goodyear HM, Harper JL. "Wet-wrap" dressings for eczema: an effective treatment 
but not to be misused. Br. J Dermatol 2002; 146(1):159 
  
Chapter     
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aims of the thesis 
 
 
 
 
 
Aims of the thesis  21-134 
Aims of the thesis 
This thesis is based on the clinical care for patients with severe and/or refractory AD, 
focussing mostly on the pediatric population. The diagnostic work-up as well as disease 
management in these patients differs from that in patients with mild or moderate disease, 
as has been described above. The following aims of the thesis were formulated. 
1. To evaluate the additional value of the atopy patch test within the current diagnostic 
protocol of the Pediatric Dermatology Unit of the Erasmus MC-Sophia Children’s 
Hospital for the diagnosis of a relevant food allergy in young children with AD. 
[chapter 3]  
2. To evaluate the presence of positive atopy patch test reactions to aero-allergens in 
young children with atopic dermatitis, including their correlation with elevated levels 
of serum specific IgE and/or the presence of positive skin prick tests against these 
allergens.[chapter 3] 
3. To evaluate plasma MMP-9 as a possible objective laboratory marker for the severity 
of AD [chapter 4] 
4. To further substantiate and optimize wet-wrap treatment with diluted topical 
corticosteroids as an intervention treatment in severe and/or refractory AD.  
[chapter 5] 
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The atopy patch test in the diagnostic work-up of 
pediatric patients with atopic dermatitis 
 
 
The prevalence of positive reactions in the atopy patch test with aeroallergens and 
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Background  
The atopy patch test (APT) was proposed to evaluate IgE-mediated sensitizations in 
patients with atopic eczema (AE). 
 
Objective  
The prevalence and agreement with clinical history and specific IgE (sIgE) of positive 
APT reactions was investigated in six European countries using a standardized method. 
 
Methods  
A total of 314 patients with AE in remission were tested in 12 study centers on 
clinically uninvolved, non-abraded back skin with 200 index of reactivity (IR)/g of house 
dust mite Dermatophagoides pteronyssinus, cat dander, grass, and birch pollen allergen 
extracts with defined major allergen contents in petrolatum. Extracts of egg white, celery 
and wheat flour with defined protein content were also patch tested. APT values were 
evaluated at 24, 48, and 72 h according to the European Task Force on Atopic Dermatitis 
(ETFAD) guidelines. In addition, skin-prick test (SPT) and sIgE and a detailed history on 
allergen-induced eczema flares were obtained. 
 
Results  
Previous eczema flares, after contact with specific allergens, were reported in 1% 
(celery) to 34% (D. pteronyssinus) of patients. The frequency of clear-cut positive APT 
reactions ranged from 39% with D. pteronyssinus to 9% with celery. All ETFAD intensities 
occured after 48 and 72 h. Positive SPT (16–57%) and elevated sIgE (19–59%) results were 
more frequent. Clear-cut positive APT with all SPT and sIgE testing negative was seen in 7% 
of the patients, whereas a positive APT without SPT or sIgE for the respective allergen was 
seen in 17% of the patients. APT, SPT and sIgE results showed significant  agreement with 
history for grass pollen and egg white (two-sided Pr > |Z| ≤ 0.01). In addition, SPT and sIgE 
showed significant agreement with history for the other aeroallergens. With regard to 
clinical history, the APT had a higher specificity (64–91% depending on the allergen) than 
SPT (50–85%) or sIgE (52–85%). Positive APT were associated with longer duration of eczema 
flares and showed regional differences. In 10 non-atopic controls, no positive APT reaction 
was seen. 
 
Conclusion  
Aeroallergens and food allergens are able to elicit eczematous skin reactions after 
epicutaneous application. As no gold standard for aeroallergen provocation in AE exists, 
the relevance of aeroallergens for AE flares may be evaluated by APT in addition to SPT 
and sIgE. The data may contribute to the international standardization of the APT. 
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Introduction 
Atopic eczema [atopic dermatitis (AE)] is an inflammatory, chronically relapsing, non-
contagious and extremely pruritic skin disease. Atopic sensitization with increased total 
and specific immunoglobulin E (sIgE) levels is a common finding in patients suffering from 
AE [for review, see Ref. (1, 2)]. Although the role of allergy in AE is still controversial, 
some patients with atopic eczema suffer from exacerbation of skin lesions after contact 
with or inhalation of aeroallergens, e.g. house dust mite (Dermatophagoides 
pteronyssinus), pollen, animal dander or after ingestion of allergy-inducing foods and 
improve after appropriate avoidance strategies (3,4). It has been repeatedly shown that in 
certain patients, eczematous skin lesions can be induced by epicutaneous application of 
aeroallergens, e.g. house dust mite [for review, see Ref. (5, 6)]. This test procedure, an 
epicutaneous patch test using allergens shown to induce IgE-mediated sensitizations and 
the evaluation of an eczematous skin reaction, is called “atopy patch test” (APT) (7). 
Studies describing experimental patch testing with aeroallergens were published as early 
as 1937 by Rostenberg and Sulzberger (8) and in 1982 by Mitchell et al. (9); the methods 
and results used since then have shown wide variations. Potentially irritating procedures 
like skin abrasion (10, 11), tape stripping (6, 12) and sodium lauryl sulphate application 
(13) were used to enhance allergen penetration. 
For better standardization, we performed APT on non-lesional, non-abraded, 
untreated skin during remission (7,14). The results were compared for the vehicle and dose 
of allergen in the preparations used. It was shown that healthy controls and patients with 
respiratory atopy without a history of eczema do not react to the APT (14) or with a lower 
frequency and intensity of APT reactions to whole-body mite extract compared with 
patients with AE (15). Sensitivity and specificity of different diagnostic procedures were 
calculated in a previous multicenter study (16). Here, we present the results of a 
prospective European multicenter trial with biologically standardized APT preparations and 
corresponding allergy diagnosis in 314 patients with AE. This study was designed to define 
appropriate APT methods, safety aspects and relationship to clinical history of eczema 
flares using the most common allergens known to elicit reactions in AE patients in Europe. 
Another aim of the study was to determine the number of individuals with positive APT 
reactions, but negative sIgE (formerly diagnosed as “intrinsic-type AE”) in a larger patient 
group and to see whether the patients’ history to a certain allergen is in agreement with 
the APT reaction, thus suggesting an important diagnostic role of the APT.  
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Methods 
Patients 
After approval by the local ethics committees and obtaining informed, written 
consent, 314 patients [age range 1.6–80 years; 177 female: mean age 22.6 ± 14.3 years 
(median 22.09); 137 male: mean age 22.9 ± 17.3 years (median 21.63)] with atopic eczema 
(1, 2) in actual remission, i.e. in a stable phase without acute flares of eczema, were 
enrolled in 12 study centers. The group included 76 (24%) children ( ≤ 10 years). There was 
no previous selection of patients for prior APT reactivity. using the same standardized 
documentation forms for test results and clinical history in all study centers, all patients 
were examined for distribution of (residual) eczematous skin lesions and their history was 
recorded with regard to atopic diseases, AE duration, previous exacerbations 
(documentation in forms with regard to every single allergen tested, e.g. for seasonal 
eczema flares in previous years), previous location of eczema and demographic items. 
Mean duration of AE was 5.8 ± 5.5 years; 59% had a history of allergic rhinoconjunctivitis, 
35% bronchial asthma and 23% urticaria. Before testing, patients were asked whether they 
experienced eczema flares and itching after contact with house dust or cat. Repeated 
seasonal variations of eczema severity or sudden, recurrent flares during the birch or grass 
pollen season (April/May and June to August) were also recorded. In addition, history 
comprised questions on eczema flares after ingestion of foods with special regard to egg, 
wheat and celery. 10 healthy, non-atopic volunteers (mean age 26.5 ± 1.2 years, five 
females) without positive skin-prick test (SPT) or elevated sIgE levels or other signs of 
atopy were included as controls. 
 
Materials, atopy patch test design and reading 
Aeroallergen APT were performed with extracts containing 200 index of reactivity 
(IR)/g of house dust mite D. pteronyssinus, cat dander, grass and birch pollen allergens in a 
petrolatum vehicle (Stallergènes, Antony, France). The potency of 100 IR was designated 
as the strength of allergenic extract that elicited a geometric mean wheal diameter of 7 
mm on SPT in 30 subjects sensitive to the corresponding allergen. Major allergen contents 
(only available for aeroallergens) are given in Table 1. Extracts of egg white, wheat flour 
and celery were tested and standardized for protein content in petrolatum and protein 
contents are also shown in Table 1. After discontinuation of antihistamines, and systemic 
and topical steroids for at least 5 days, the test substances were applied in a randomized, 
double-blind design for 48 h in Large Finn Chambers (diameter 12 mm; Epitest Ltd, Oy, 
Finland) on clinically uninvolved, not pretreated back skin. All reactions were evaluated 
after 24 reapplied), 48 and 72 h and compared with simultaneously performed 
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corresponding SPT (Stallergènes), and specific sIgE [CAP-radioallergosorbent test (RAST)-
flurescence enzyme immunoassay; Pharmacia, Uppsala, Sweden] as classical methods for 
diagnosing type I sensitizations. Grading of positive APT reactions was similar to the 
criteria used in conventional contact allergy patch testing [International Contact 
Dermatitis Research Group (ICDRG) rules] with the modifications of the European Task 
Force on Atopic Dermatitis (ETFAD) Consensus Meetings (17); i.e. -, negative result; ?, only 
erythema, questionable; +, erythema, infiltration; ++, erythema, few papules (up to 3); 
+++, erythema, papules from 4 to < many; ++++, erythema, many or spreading papules; 
+++++, erythema, vesicles. A patch test with the pure vehicle served as negative control.  
 
 
Major allergen concentrations in the extracts (200 IR/g) (µg/ml) (ELISA)  
House dust mite  
  Der p 1 59 
  Der p 2 6 
Cat Dander  
  Fel d 1 9 
Grass pollen  
  Phl p 1 2 
Birch pollen  
  Bet v 1 165 
  
Protein concentrations (µg/ml) (Bradford Method)  
  House dust mite 98 
  Cat dander 75 
  Grass pollen 132 
  Birch pollen 334 
  Wheat 158 
  Celery 44 
  Egg white 740 
 
Table 1  
APT material: allergen and total protein content. Vehicle: petrolatum. For food patch test 
preparations, only standardized protein content was available. 
 
 
All investigators participated in pre-study standardized test reading sessions. Test 
application and reading were performed by different investigators. Thus, reading of 
reactions was performed by an investigator without the knowledge of the (control) test 
sites or  patient’s history. Only reactions from + (i.e. erythema, infiltration) onwards were 
designated clear-cut positive. The APT procedure in this study was performed in the same 
way as in our previous studies on AE patients and healthy controls (14, 16). 
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Statistics 
Statistical analysis of the data was performed with SPSS-Software using chi-square 
and linear association tests. After checking for normal distribution, paired t-test was used 
to compare mean rates of positive APT reactions, SPT and elevated sIgE in the study 
centers. Multivariate analysis was performed using a logistic regression model of APT 
outcome predictors. 
 
 
Results 
Patients’ history of exacerbation after allergen contact/ingestion  
10–39% of the patients reported eczema exacerbations after aeroallergen contact, 
mostly to house dust mite. Seasonal flares were reported in 17%. Food allergens were 
suspected in 1–7% of this mostly adult population. Table 2 shows the history in comparison 
with other clinical variables. 
 
 
Allergen SPT sIGE APT History Concordance 
Dermatophagoides pteronyssinus 56 56 39 34 57 
Birch pollen 49 53 17 20 61 
Grass pollen 57 59 15 31 64 
Cat dander 44 46 10 30 62 
Egg white 25 19 11 7 77 
Wheat flower 16 38 10 3 78 
Celery 20 30 9 1 79 
 
Table 2  
Positive test results and patients’ history of allergen associated eczema flare. All values are 
percentage values. Frequency of positive APT reactions is lower than that of positive IgE-mediate 
sensitizations. Patients’ allergen specific history of eczema flares after allergen exposure was 
obtained prospectively. Concordance refers to APT and history. 
N=314, 24% children ≤ 10 years. 
SPT, skin prick test ≥ 3 mm; sIgE, specific IgE ≥ 0.35 kU/l; APT, atopy patch test ≥ +. 
 
 
 
Eczema pattern 
A total of 113 of the 314 patients (37%) reported skin lesions only in areas not 
covered by clothing and therefore a predictive eczema pattern for aeroallergen contact: 
the neck, face and scalp, hands and arms (over the last 12 months). 
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Skin-prick test and specific IgE 
The frequencies of positive test results are given in Table 2. Concerning one allergen, 
the frequencies of SPT and sIgE, the classical tests of IgE-mediated hypersensitivity, were 
very similar to each other (except for wheat flour) and always higher compared with the 
frequency of a predictive history or positive APT. SPT reactions with a wheal diameter <3 
mm were regarded as negative.  
 
Atopy patch test 
All tested allergen preparations were able to elicit positive, clear-cut eczematous 
reactions in subgroups of patients, but not in control subjects. Positive reaction to the 
vehicle control area was only seen in three of 302 patients (0.99%). The frequency of the 
positive APT reactions is also given in Table 2. Whereas food allergens elicited positive 
reactions in the investigated population in about 10%, the most frequent allergen causing 
positive APT was D. pteronyssinus (39%), followed by pollen allergens. An example of a 
positive APT reaction is shown in Fig. 1. Higher frequencies of positive APT reactions to 
food allergens were seen in children compared with adults (wheat flour: 15% vs 8%; celery: 
12% vs 8%) except for egg white (both 11%).  
  
 
 
Figure 1 
APT reactions to different allergens after removal of Finn Chambers after 48 h. Clear-cut 
eczematous appearance with infiltration and spreading papules, partially with a follicular pattern. 
Control: petrolatum. 
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The reactions to D. pteronyssinus are given in Fig. 2 with regard to their frequency at 
different timepoints and their intensity distribution. The results of other allergens are 
distributed similarly (not shown). Figure 2 also demonstrates, as an example, that at 24 h 
after application, only very few positive reactions were seen. Evaluations of APT after 48 
and 72 h gave more frequently clear-cut positive reactions than after 24 h. Using the 
differentiated reading key of the ETFAD, the intensity of positive APT reactions is 
distributed similar to a logarithmic normal distribution. 
 
 
 
 
Figure 2 
APT ETFAD grading: reaction frequencies of different intensities and time points. Distribution of 
patients with different APT reading key units according to ETFAD Consensus Meetings (17) for the 
most frequent allergen, house dust mite (D. pteronyssinus). After 24 h, positive APT reactions were 
rare. APT reading after 48 and 72 h is recommended (n=314). 
 
  
 
Agreement analysis: history, skin prick test, specific IgE, eczema pattern 
For grass pollen and egg white, APT, SPT and sIgE results showed significant 
concordance with a  prospectively obtained predictive history of eczema exacerbations 
(two-sided Pr>|Z|≤ 0.01). In addition, SPT and sIgE showed significant agreement with 
history for the other  aeroallergens. In 83% of patients, corresponding SPT or sIgE results 
were found to match with the individual positive APT. A subgroup of patients was 
characterized by negative SPT and  sIgE, but clear-cut positive APT results. There were 22 
patients (7%) with clear-cut positive APT but without any positive SPT or elevated sIgE to 
all the allergens in the panel. With regard to a single APT-positive allergen, this was seen 
in 53 (17%) of the patients. No significant difference in the agreement with history was 
seen when comparing these patients with the IgE-positive group. The distribution of 
allergens is shown in Fig. 3. 
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Figure 3 
• Observed in 53 of 314 patients (17%) 
• N=22 APT+, but no positive SPT or sIgE at all (7%) 
Patient subgroup with at least one positive APT reaction without corresponding skin-prick test / 
specific IgE. Clear-cut positive APT with all SPT and sIgE tested negative was seen in 7% of the 
patients, whereas a positive APT without SPT or sIgE for the respective allergen was seen in 17% of 
the patients 
 
 
No significant association between air-exposed eczema distribution pattern and a 
positive APT result was seen (P > 0.05, n=188). The duration of the last eczema flare in 
patients with at least one allergen with positive APT reaction (n=84) was 186 ± 380 days 
(median 105 days). In patients with negative APT (n=104), the duration was shorter: 143 ± 
278 days (median 82 days; difference not significant, P > 0.05). 
 
 
 Sensitivity  Specificity 
Test SPT sIgE APT  SPT sIgE APT 
Dermatophagoides 
pteronyssinus 
68* 72* 45  50* 53* 64 
Cat dander 79* 80* 14  71* 69* 91 
Grass pollen 80* 84* 28*  54* 53* 91* 
Birch pollen 69* 73* 15  57* 52* 83 
Egg white 68* 59* 32*  78* 85* 91* 
Celery 100* 50 33  81* 71 91 
Wheat flower 30* 78 30  85* 63* 91 
 
Table 3.  
Sensitivity and specificity of different test procedures with regard to patients’ history. All values 
are percentage values. Referring to predictive history of eczema exacerbations in pollen season, in 
direct contact with allergen, or after food ingestion (n=314). 
* Agreement with history (two-sided Pr>|Z|≤ 0.01). 
The APT shows a higher specificity than classical tests for IgE-mediated hypersensitivity with regard 
to the allergen-specific history. 
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Sensitivity and specificity of different test procedures  
The accuracy parameters sensitivity and specificity were calculated for all allergens 
and compared with the classic tests of IgE-mediated hypersensitivity (Table 3). The criteria 
for a “true positive” test was, as usual in epicutaneous testing, a corresponding predictive 
history of the patient with the investigated allergen. It could be demonstrated in all tested 
allergens, that the specificity of the APT was always higher than the specificity of SPT or 
RAST. However, the sensitivity was lower, depending on the allergen studied. 
 
Regional differences of APT reactivity  
Table 4 shows the mean percentages of patients with positive APT reactions to the 
four tested  aeroallergens, in comparison with different countries. Marked differences 
were seen in these numbers, especially for the seasonal pollen allergens and for cat 
dander. Less positive reactions to pollen were obtained in Switzerland, France and Italy 
compared with the Netherlands, Belgium and Germany. No significant regional differences 
were observed for food allergens (not shown). Comparing the percentual frequencies of 
positive APT and corresponding elevated allergen-specific serum IgE per center, a paired t-
test analysis showed significant association of these parameters for cat, grass and birch 
pollen.  
 
 Allergen 
 
Country 
Dermatophagoides 
pteronyssinus 
 
Cat* 
 
GP* 
 
BP* 
The Netherlands (n=36, 2 centers) 42 3 16 22 
Belgium (n=32, 2 centers) 44 13 8 19 
Germany (n=162, 4 centers)1 36 11 20 21 
Switzerland (n=42, 2 centers) 40 5 5 2 
France (n=9, 1 center)2 67 11 0 11 
Italy (n=30, 1 center) 17 10 7 7 
 
Table 4 
Percentage of positive APT per allergen per country. All values are percentage values. Regional 
differences of APT reactions were seen. 
1 Including German Clinic in Davos, Switzerland. 
2 Pediatric study center. 
* Association of APT with specific IgE, p< 0.05  
 
 
Adverse events 
In 25 of 314 patients (7.7%), adverse side-effects were reported, described as local 
eczema flares, contact urticaria, irritation caused by adhesives, and itching in test sites, 
some of which required topical therapy. One event was graded as severe, where a patient 
developed breathing problems in the night following APT and SPT. After removing of the 
APT and a lung X-ray, the patient recovered. A causal relation to the APT was unlikely. 
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Discussion 
This is the first international multicenter study describing the feasibility of APT in a 
clinical setting with a controlled, double-blind design. The results of this study confirm 
that aeroallergens and food allergens are able to elicit eczematous skin lesions in a 
number of patients with atopic eczema when applied  epicutaneously on untreated skin. 
The methodology used, in contrast to many experimental models for APT, is suitable for 
allergological routine, can be standardized across many sites, and can be interpreted on a 
clinical background in patients with atopic eczema. 
As a “gold standard” of aeroallergen provocation test in atopic eczema does not 
exist, the individual allergen-specific history of previous eczema exacerbations was used 
like in conventional contact allergy testing as a substitute for a relevance parameter. For 
aeroallergens, patient’s history has previously been shown to be suitable to evaluate 
clinical relevance, especially for seasonal allergens (16, 17). Food provocation challenges 
were not included as no international standardization was achieved a priori and feasibility 
is large-scaled. In this study, significant associations of APT results with the prospectively 
obtained history were seen with exposure to grass pollen as seasonal allergen and egg 
white as most frequent food allergen. 
Atopy patch test evaluation after 48 and 72 h gave the number of positive APT 
results; however, after 24 h no relevant results could be obtained. The two later reading 
timepoints should be considered relevant in patch testing with aeroallergens; Fig. 2 shows 
a 10% higher frequency at 48 h compared with 72 h, for most positive APT key units. In 
addition, the distribution of APT reading key units in this multicenter study indicates the 
suitability of the ETFAD key for clinical routine. The cutoff of a positive APT reaction 
needing to be at least infiltrated (not only erythema) has previously been used successfully 
(14, 16); a visual score was recently shown to be superior in differentiation between 
irritative and allergic reactions compared with chromametry and laser Doppler imaging 
(18). 
The sensitivity analysis, in comparison with previous studies (16, 17), suggests that 
for some allergens APT allergen concentrations >200 IR/g may be necessary to demonstrate 
a sensitization. Further studies with larger numbers of (pediatric) patients and including 
food challenges are necessary for food allergens, after better standardization of the 
allergen content. Celery was included as a known cross-allergen in adults (age >10 years in 
76% of the study group) and indeed the number of patients with a positive APT to celery is 
markedly higher than the number of patients with a history of celery-associated eczema 
flares (Table 2). As a result of the overall low reactivity to celery APT and the lack of food 
provocation, these associations should be interpreted cautiously. Milk as a relevant food 
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allergen in children could not be produced in a standardized APT preparation for this 
study. Higher numbers for sensitivity and specificity of APT with unprocessed native food 
were reported by Niggemann et al. (19) and Roehr et al. (20), using food provocation 
outcomes as calculation basis.  
The regional subgroup analysis of this international multicenter study showed wide 
variations in the rate of positive APT reactions in spite of the highly standardized test 
procedure. This observation may partially explain the different outcomes of previous APT 
studies from different countries. Differences in patients’ sensitization rates, probably due 
to different allergen exposure to certain aeroallergens may be one reason for this 
variation. This hypothesis is sustained by the significant association of the APT positivity 
rate and the corresponding specific IgE in the centers, arguing against investigator bias in 
APT reading (which was also standardized in training sessions). 
The association of positive APT with specific IgE to certain allergens in this study 
suggests the role of allergenspecific IgE in the development of eczematous skin lesions 
after allergen contact in this study and confirms previous results (16). Mite allergen in the 
epidermis under natural conditions (21) as well as in APT sites (10, 13) has been 
demonstrated in proximity to Langerhans cells. Langerhans cells in the skin express IgE 
receptors of three different classes (22–24). In addition, a Birbeck granule negative, non-
Langerhans cell population with an even higher IgE-receptor expression than the 
Langerhans cell, the so-called inflammatory dendritic epidermal cell (IDEC), has recently 
been demonstrated in freshly induced APT lesions (25, 26), a phenomenon which occurred 
in both “intrinsic” and “extrinsic” patients (26). This might explain IgE-associated 
activation of allergenspecific T cells finally leading to eczematous skin lesions in the APT 
(27, 28). According to the results of Langeveld-Wildschut et al. (29) the positive APT 
reaction requires the presence of epidermal IgE+ CD1a+ cells. 
That classical IgE-mediated tests like SPT and the proof of sIgE by CAP-RAST show 
positive reactions in the majority of patients with AE (1, 5, 14, 18), could also be 
demonstrated in this study. However, these tests are of low specificity. In contrast, the 
APT was associated with the more specific information, which patient really experienced 
deterioration of AE after aeroallergen contact. Therefore, the outcome of APT can only 
partially be predicted by sIgE, SPT or history, which, alone or in combination, can only be 
a substitute for the specific provocation or allergen avoidance measures. The very low 
frequency of reactions to vehicle control tests and the high number of positive reactions to 
allergen-carrying test substances in this study demonstrates the advantage of an APT 
method without irritating procedures like tape stripping or abrading to enhance allergen 
penetration. 
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In some patients with negative SPT with or without sIgE, clear-cut positive APT reactions 
were observed. It is well known that SPT and sIgE are not perfectly concordant when 
compared in a larger group of patients, since they may indicate sensitization in different 
compartments of the body (i.e. IgE on skin mast cells or in the serum). In contrast to SPT 
and sIgE, the APT gives additional information on another pathophysiological aspect, 
eczematous skin inflammation. 
In summary, APT is not proposed as a single screening test in patients with atopic 
eczema. It may rather be used in addition to SPT and sIgE as a tool to prove clinical 
relevance of a given sensitization. A sensitization detected by APT, which is supposedly T-
cell mediated, may be even more relevant for the clinical course of atopic eczema than 
the demonstration of an IgE-mediated sensitization. However, without the clear-cut 
positive APT, 7% of the tested patients who would be labelled as “intrinsic type” of atopic 
eczema according to Wüthrich’s definition (30), show a sensitization in the APT. A similar 
finding of positive APT reactions in subjects without sIgE to Dermatophagoides was 
described by Seidenari et al. (31) and Manzini et al. (32). Moreover, recently eight of 12 
“intrinsic” atopic eczema patients were reported to react to a partially purified whole-
mite APT preparation by Ingordo et al. (33). Similar results have been obtained by APT 
with Malassezia sympodialis antigen (34). House dust mite-specific antibodies of the IgG4 
subtype, as well as a rapid influx of IDEC in the APT lesions has recently 
been reported in two otherwise “intrinsic” atopic eczema patients (35). However, the 
mechanism of these “intrinsic” APT reactions remains hypothetical to date, but a T-cell 
mediated mechanism without IgE involvement seems probable. With regard to the recently 
proposed novel nomenclature for allergy by the European Academy of Allergy and Clinical 
Immunology (36), these cases may be diagnosed as “non-IgE-associated AEDS” or “T-cell-
mediated AEDS”, respectively. 
The APT model used in this study with standardization of allergen concentration 
and vehicle may provide an important diagnostic tool to select those patients who show 
special benefit from allergen avoidance procedures or allergen-specific immunotherapy 
(37). To date, there are no data from intervention studies supporting that patients with 
positive APT benefit from allergen avoidance (38, 39). The APT with allergens in 
petrolatum may be used in the future as a kind of provocation test on the skin, but food 
challenge tests as gold standard in food allergic patients with AE are not replaced. The APT 
may even identify those patients with negative SPT and sIgE. However, the clinical 
relevance of positive APT reactions is still to be proven by standardized provocation and 
avoidance tests and may also depend on the APT model used and outcome definitions. 
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In recent years the Atopy Patch Test (APT) has been suggested as an addition in the 
allergologic work-up of children with AD and suspected food allergy. We initiated a 
prospective clinical study in children with atopic dermatitis (AD) younger than 3 years, to 
evaluate the additional clinical value of the atopy patch test (APT) next to our own 
standardized allergologic work-up in case of a suspected food allergy. 
 
One hundred and thirty-five children were included in the study. They were tested 
using the skin application food test (SAFT), the APT and measurement of specific IgE. The 
allergens used in the skin tests were freshly prepared food stuffs and included 
commercially available cow’s milk (CM), the egg white of a hard boiled hen’s egg and 
mashed peanuts in a saline solution. Allergy was defined using a flow-chart incorporating 
the results from the SAFT, oral challenges (OCs) and elimination and (re)introduction 
periods. To determine the additional value of the APT next to the SAFT, we analyzed the 
SAFT negative patients per allergen and used an exact binary logistic analysis to evaluate 
the simultaneous effects of the APT and measurement of specific IgE, calculating mutually 
adjusted odds ratios (OR’s) for positive APT’s and specific IgE levels above 0.70 U/l.  
 
We found clinically relevant food allergies in 23% (egg white) to 28% (cow’s milk and 
peanut) of our study population. Positive SAFT reactions were observed in 14% (peanut), 
16% (egg white) and 21% (cow’s milk) of our patient population. Next to the SAFT we did 
not observe a significant additional value of the APT for the diagnosis of cow’s milk or egg 
white allergy, but we did find a significant additional value for the diagnosis of peanut 
allergy (OR 11.56; p<0.005, 2-sided). In clinical practice this statistically significant value 
does not exclude the need for OC and controlled elimination and (re)introduction periods 
due to the presence of false negative as well as false positive results in the APT.  
 
In conclusion we could not find enough support for the current addition of the APT to 
our standardized allergologic work-up in young children below the age of three years with 
AD and suspected food allergy. At the moment the additional value of the classical delayed 
type APT next to the SAFT seems to be very limited at best in this study population and 
does not justify the time consuming nature of the skin test. 
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Introduction 
Atopic dermatitis is a chronic multifactor inflammatory skin disease with a genetic 
background. It is part of the so-called atopic syndrome and may be associated with a 
sensibilisation for food allergens, especially in childhood. Although the clinical relevance 
of this sensibilisation is not always clear, there is a small sub-population of children with 
AD who do develop clinically relevant reactions to different food allergens. This group may 
benefit from dietary measurements and needs to be separated from the majority of 
children with AD in whom diets are not beneficial. 
The allergologic work-up in children with AD and suspected food allergy starts with a 
careful history and clinical examination. Additional tests usually include the Skin Prick Test 
(SPT) and/or measurement of serum specific IgE, both aimed at revealing immediate type 
sensibilisation against the allergens tested. The Skin Application Food Test (SAFT) has been 
described as a reliable and child friendly alternative to the SPT in children with AD below 
the age of 3 years.1 The gold standard for the diagnosis of a food allergy is still an oral 
challenge (OC), preferably double blind placebo controlled and followed by a supervised 
reintroduction period.2 Although OC are time-consuming and carry a certain risk, they may 
be necessary in cases were serology, skin tests and history do not reveal a conclusive 
result. 
In recent years the Atopy Patch Test (APT) has been suggested as an addition in the 
allergologic work-up of children with AD and suspected food allergy.3,4,5 The APT is aimed 
at detecting delayed type, eczematous, allergic reactions to allergens commonly 
associated with direct type, IgE mediated, allergic reactions. It’s addition is advocated as 
a means to reduce the number of OC necessary in order to reach a conclusive result.6,7 
Although in theory the combination of a skin test aimed at immediate type allergic 
reactions (SPT or SAFT) and a skin test aimed at delayed type allergic reactions (APT) 
seems promising, there have been conflicting results published regarding the clinical value 
of the APT in daily practice.3-10  
We initiated a prospective clinical study in children with AD younger than 3 years, to 
evaluate the additional clinical value of the APT next to our own standardized allergologic 
work-up in case of a suspected food allergy. 
 
Materials and Methods 
The study was performed on the paediatric dermatology out-patient clinic of the 
Erasmus MC-Sophia Children’s Hospital. Children aged 0-3 years with AD and an indication 
for an allergologic work-up, were eligible for inclusion. AD was defined by the criteria of 
Williams et al.11 Indications for an allergologic work-up consisted of suspected food 
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allergies due to reported reactions, pre-existing diets or refractory skin disease. The 
inclusion period lasted 2 years and 10 months. 
Patients were subjected to our standardized work-up consisting of a careful history, 
focusing on clinical signs of food-allergy, combined with the SAFT and measurement of 
specific IgE. The allergens used in the skin test were freshly prepared food stuffs and 
included commercially available cow’s milk (CM), the egg white of a hard boiled hen’s egg 
and mashed peanuts in a saline solution. There was no further dilution of the allergens and 
the foodstuffs were tested in the form in which they would be eaten. In addition the APT 
was performed, using the same allergens as were used in the SAFT.  
 
Skin Application Food Test 
SAFT were performed on the unabraded volar aspects of the lower and if necessary 
upper arm, using medium (8 mm) Finn-chambers on scanpor. A saline solution was used as 
a negative control. They were read after 10, 20 and 30 minutes. The skin test was removed 
after 30 minutes or earlier if an urticarial weal and flare response occurred during the 
prior reading times. Evaluation took place using a scale from 0-3 with 0 indicating no 
reaction, 1+ erythema only, 2+ urticarial weals within the test area and 3+ urticarial weals 
spreading beyond the test area. Only 2+ and 3+ reactions were regarded as positive.1 
 
Atopy Patch Tests 
APT were performed on the unabraded skin of the back using large (12 mm) Finn-
chambers on scanpor. A saline solution was tested as a negative control. If the above 
mentioned SAFT test was positive the APT was removed. After 20-30 minutes the remaining 
test areas were examined as well, to make sure there was no urticarial weal and flare 
reaction, in which case the skin test would also be removed. Subsequently the Finn 
chambers were covered with fixomull, to prevent them from shifting. The skin tests were 
removed after 24 hours, because we feared possible putrefication of the fresh foods might 
lead to false positive results. The APT was evaluated after 48 and 72 hours, using the 
guidelines described by the European Taskforce on Atopic Dermatitis (ETFAD).12 Only clear-
cut reactions of 2+ or more were regarded as positive. 
 
Specific IgE     
Blood was drawn from each patient. Allergen-specific IgE was measured in serum with 
the CAP system (Pharmacia, Woerden, The Netherlands) according to the manufacturer's 
instructions. Only levels of 0,70 U/l or more were regarded as positive. 
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Definition of allergy for this study 
Figure 1 shows the flow chart used to identify a relevant allergy for any of the three 
food stuffs. The first step in this chart is based on the results from the SAFT, which has 
shown a positive predictive value of 100%, as our study group reported previously.1 
 
 
 
 
Figure 1 
Flow-chart used to identify a relevant allergy in our study population. SAFT=skin application food test; 
APT=atopy patch test; AD=atopic dermatitis; OC=oral challenge. 
 
 
Oral challengens 
Oral challenges (OC) were performed in our day-care unit. Below the age of two 
years we generally performed the OC open. When specific IgE levels were above 0,70 U/l 
they were performed giving the suspected food stuffs in 5 steps with a slowly increasing 
dose and 1 hour between each step. The total duration of the OC was 8 hours. Safety 
measures included a capped off infusion needle inserted in an arm vein before the start of 
the OC. Adequately dosed clemastine, epinephrine and hydrocortison infusion fluids were 
prepared based on the weight of the patient. When specific IgE values were below 0,70 U/l 
the total duration of the OC was shortened and the suspected food stuff was given in 3 
steps with a more rapidly increasing dosage and 15 minutes between each step (bulk 
provocation). Adequately dosed medication as described above was prepared but the 
infusion needle was not inserted. A qualified paediatric nurse was present during the 
entire duration of the challenges. After a negative oral challenge a monitored introduction 
period of 4-6 weeks was initiated (see below) 
 
Test results 
SAFT positive 
 
Relevant allergy 
SAFT negative 
Preexisting diet No diet 
Positive OC 
 
Relevant allergy 
Negative OC Moderate/severe AD mild AD 
 
No relevant allergy 
 
Positive elimination  
/introduction 
Relevant allergy 
 
Negative elimination 
/introduction  
No relevant allergy 
 
Positive introduction 
/elimination 
Relevant allergy 
 
Negative 
introduction  
No relevant allergy 
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Food elimination and (re)introduction 
Elimination and/or introduction periods for a single food allergen lasted 4-6 weeks. 
Before and after each episode an evaluation by a research physician took place. Parents 
were educated and monitored by a qualified dietician with experience in paediatric 
patients with food allergies. 
 
Ethical aspects and statistical analysis 
The study was approved by the Medical Ethics Committee of the Erasmus MC. The 
parents of all patients signed informed consent. The statistical analysis was performed 
using SPSS version 11.0 and LogXact version 4.1.  
 
 
Results 
One hundred and forty eight children were eligible for inclusion. We experienced 13 
dropouts due to active skin disease on the test areas (n=8), very strong positive 
dermography (n=1), multiple positive APT reactions, including the negative control (angry 
back, n=3) and 1 child who developed fever based on an airway infection during the test 
week. The remaining 135 children included 33 children below the age of 1 year and 102 
children between 1 and 3 years of age. 
We were unable to collect complete data concerning the presence of allergy in 34 
patients representing 50 APT tests. This was mainly caused by failure to complete the 
process of OC and/or elimination and (re)introduction in a timely manner because of 
parents refusing an OC (n=14) or loss during follow up (n=17). Reasons for refusing an OC 
consisted of anxiety concerning the OC procedure, especially placement of the infusion 
needle or the wish to continue the diet anyway due to believed preventive properties of 
the diet or the presence of family members with an allergy already making a “family diet” 
necessary. One patient suffered from a concomitant gastro-intestinal disorder other than 
food allergy and needed continuation of hypoallergenic milk substitution and  two patients 
had their OC cancelled due to the failed insertion of an infusion needle and an 
exacerbation of AD prior to the OC respectively.   
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 SAFT APT Additionally diagnosed 
allergy 
 Positive Negative Positive Negative Positive Negative 
Cow’s milk 
 
26 
(n=125) 
99 
(n=125) 
7 
(n=99) 
92 
(n=99) 
9 
(n=99) 
90 
(n=99) 
Egg white 
 
19 
(n=120) 
101 
(n=120) 
11 
(n=101) 
90 
(n=101) 
7 
(n=101) 
94 
(n=101) 
Peanut 
 
15 
(n=110) 
95 
(n=110) 
18 
(n=95) 
77 
(n=95) 
15 
n=95) 
80 
(n=95) 
 
Table 1 
Number of positive and negative Skin Application Food Tests (SAFT), Atopy Patch Tests (APT) and Additionally 
diagnosed allergy. APT were only performed in SAFT negative patients.  The additional diagnosis of food allergy 
was made in SAFT negative patients using oral challenges and elimination/reintroduction periods as defined in 
the flow chart in fig. 1.   
 
Cow’s milk 
In 10 patients the data concerning allergy was incomplete. The remaining 125 
patients included 26 patients (21%) with a positive SAFT reaction. Nine additional patients 
(7%) were later diagnosed with food allergy and 90 patients (72%) were diagnosed as having 
no food allergy (Table 1). Using Fisher’s exact test there seemed to be a significant 
additional value of the APT in proving the diagnosis cow’s milk allergy in the SAFT negative 
patient group (p=0.015, 2-sided). Likewise the presence of specific IgE also showed a 
significant additional value (p=0.014, 2-sided). We used exact binary logistic regression 
analysis to evaluate the simultaneous effects of the APT and specific IgE (Table 2). The 
mutually adjusted odds ratios (OR’s) for a positive APT and specific IgE above 0.70 U/l are 
9.61 and 5.58 respectively. However, the OR of the APT, adjusted for specific IgE, is not 
significant (p=0.051, 2-sided) and the OR of specific IgE, adjusted for the APT, is only 
borderline significant (p=0.047, 2-sided). 
 
 
 95% CI 
 
Odds ratio 
lower upper 
p-value 
(2-sided) 
Cow’s milk     
APT 9.61 0.99 95.52 0.051 
IgE 5.58 1.02 39.06 0.047 
Egg white     
APT 1.05 0.02 11.60 1.000 
IgE 10.37 1.49 ∞ 0.014 
Peanut     
APT 11.56 2.10 87.75 <0.005 
IgE 32.86 4.94 ∞ <0.005 
 
Table 2 
Exact binary logistic regression model listing  the odd ratios for allergy in case of a positive atopy patch test or 
specific IgE value in patients with a negative SAFT, given the combination of both tests. CI=confidence interval; 
APT=atopy patch test 
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Egg white 
In 15 patients the data concerning allergy was incomplete. The remaining 120 
patients included 19 patients (16%) with a positive SAFT reaction. Seven additional patients 
(6%) were later diagnosed with food allergy and 94 patients (78%) were diagnosed as having 
no food allergy (Table 1). Using Fisher’s exact test we found no significant additional value 
of the APT in proving the diagnosis egg white allergy in the SAFT negative patient group 
(p=0.566, 2-sided). However, the presence of specific IgE did show a significant additional 
value (p=0.013, 2-sided). In the exact binary logistic regression analysis the respective 
OR’s are 1.05 and 10.37 (Table 2). The OR of the APT, adjusted for specific IgE,  is very 
near 1 and off course not significant (p=1.000, 2-sided). The OR of specific IgE, adjusted 
for the APT, equals 10.37 and is significant (0.014, 2-sided). 
 
Peanut 
In 25 patients the data concerning allergy was incomplete. The remaining 110 
patients included 15 patients (14%) with a positive SAFT reaction. 15 additional patients 
(14%) were later diagnosed with food allergy and 80 patients (72%) were diagnosed as 
having no food allergy (Table 1). Using Fisher’s exact test we found an additional value for 
both the APT and specific IgE in proving the diagnosis peanut allergy in the SAFT negative 
patient group (both p<0.005, 2-sided). In the exact binary logistic regression analysis the 
respective mutually adjusted OR’s are 11.56 and 32.86, both significant (Table 2: p<0.005, 
2-sided).  
 
 
Discussion 
The APT could form a relevant and important addition to our allergologic work-up of 
patients with AD and a suspected food allergy. We know from previous research that the 
delayed type skin reaction in a positive APT is allergen specific, correlates with the 
presence of food allergy, is predominantly if not only observed in patients with AD and 
forms an in-vivo model of the skin lesions in AD.10 Combining skin tests aimed at immediate 
type allergic reactions, like the SPT or SAFT, with a skin test like the APT could be very 
beneficial. However, previously reported results regarding the additional value of the APT 
in the diagnosis of food allergy in children with AD are very variable. Reported sensitivity 
ranges from 18% to 93%, specificity from 41% to 97% and positive predictive values from 
40% to 96%.3-10 Some authors claim a reduced need for OC, especially when APT and SPT or 
specific IgE values are combined.6,7 Others are less enthusiastic about the value of the APT 
in daily clinical practice.8,9 Comparing the data from these studies is difficult due to 
Atopy Patch Test with food allergens  46-134 
varying patient populations, differences in methodology and interpretation of skin testing 
and differences in methodology and interpretation of OC, including the presence of 
subdivisions in early and late allergic reactions. The first steps towards standardization 
have been made, but further work is still needed.10,13-15 
Our study was initiated to determine the additional value of the APT in our 
standardized  allergological work-up of young children below the age of 3 years with AD 
and suspected food allergy. Our usual work-up in this age group consists of the SAFT and 
measurement of specific IgE with additional OC and elimination and (re)introduction 
periods if necessary. We wanted to know if the APT could identify children with a false 
negative SAFT, thus reducing our need for oral challenges and/or elimination and 
(re)introduction periods. To determine the additional value of the APT next to the SAFT, 
we analyzed the SAFT negative patients per allergen and used an exact binary logistic 
analysis to evaluate the simultaneous effects of the APT and measurement of specific IgE, 
calculating mutually adjusted OR’s for positive APT’s and specific IgE levels above 0.70 
U/l. The results showed clinically relevant food allergies in 23% (egg white) to 28% (cow’s 
milk and peanut) of our study population. Next to the SAFT we did not observe a 
significant additional value of the APT for the diagnosis of cow’s milk or egg white allergy, 
but we did find a significant additional value for the diagnosis of peanut allergy (OR 11.56; 
p<0.005, 2-sided). In clinical practice this statistically significant value does not exclude 
the need for OC and controlled elimination and (re)introduction periods due to the 
presence of false negative as well as false positive results in the APT. This concurs with the 
conclusions of Mehl et al, who found that in daily clinical practice the APT adds only a 
small predictive value to the standard SPT and sIgE measurement in the diagnostic work-up 
of suspected food allergy in children.16 
When we looked at the presence of specific IgE concentrations above 0.70 U/l, there 
was a significant additional value for this measurement next to the SAFT for diagnosing an 
allergy for peanut (OR 32.86), egg white (OR 10.37) and cow’s milk (OR 5.58). However, 
there were false negative and especially false positive values present, resulting in the 
need for continued OC and controlled elimination and (re)introduction periods. This is in 
concordance with what we know from the literature regarding the use of elevated levels of  
food-specific IgE as a test for clinically relevant food allergy.12 Especially the presence of 
false positive values but also the presence of false negative values warrants caution in the 
interpretation of this test. The group from Sampson was the first to report improved 
results by using food-specific IgE concentrations that could predict clinically relevant food 
allergy with more than 95% certainty in their study population.17,18  Although others have 
reported similar results we have not been able to determine comparable 95% predictive 
Atopy Patch Test with food allergens  47-134 
values in our own setting due to a wide variation in specific IgE levels in patients with and 
without a clinically relevant allergy [Novak J and Oranje AP, abstract ESPD congress 2005].  
Because the methodology of the SAFT and APT basically only differ with regard to 
occlusion and reading time we would expect a substantial number of urticarial reactions 
during an APT with food allergens. We also know from experience that a strong positive 
SAFT can be followed by a positive delayed type eczematous reaction after 2-3 days, even 
if the allergen is removed after 20-30 minutes [unpublished data]. We found positive SAFT 
reactions in 14% (peanut), 16% (egg white) and 21% (cow’s milk) of our patient population. 
However, data on the occurrence of urticarial APT reactions to food allergens is almost 
non-existent and if reported seems to consist of relatively low percentages.3-9,15,16 We 
suspect urticarial APT reactions are relatively underreported. This might be caused by a 
lack of inspection of the test site after 20-30 minutes. Differences in study populations 
may also play a part, as we know that contact urticaria to food allergens are 
predominantly found in younger children.19 In our own study population the question 
remains whether some or all positive SAFT reactions in our study would have turned out as 
positive APT reactions if they had not been removed. For future use we would like to 
propose to change the name of the SAFT into the immediate type APT reaction. With this 
name change we hope to prompt increased interest in the urticarial immediate type 
reactions which can be found next to the classical delayed type APT reaction, especially in 
young children with AD and food allergy.    
Our study took place in a clinical setting and is based on a large number of young 
children with AD. The drop-outs during inclusion (n=13) and the incomplete data on allergy 
(n=34 representing 50 APT tests) could in theory encompass a bias for the presence of 
allergy. However, based on the reasons why the data was not available and the fact that 
patient characteristics between patients included and excluded for statistical analysis are 
very similar, such a bias is not to be expected. 
In conclusion we could not find enough support for the current addition of the APT to 
our standardized allergologic work-up in young children below the age of three years with 
AD and suspected food allergy. At the moment the additional value of the classical delayed 
type APT next to the immediate type APT (or SAFT) seems to be very limited at best in this 
study population and does not justify the time consuming nature of the skin test. This 
conclusion is supported by a recent publication from Mehl et al.16  Further studies aimed at 
standardization, reproducibility and clinical validation are needed before the APT with 
food allergens can be used in routine daily clinical practice as a diagnostic test. Despite 
our current findings we believe these studies are worthwhile to undertake because a 
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positive APT with food allergens does function as an allergen specific delayed type 
hypersensitivity reaction, which still seems promising for further use as a diagnostic test.   
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Background 
Epicutaneous application of aeroallergens is able to elicit eczematous skin reactions 
in patients with AD. Most of the current clinical data on this so-called Atopy Patch Test 
(APT) with aeroallergens is based on adult patient populations and pediatric data is scarce. 
 
Aims of the study 
Evaluation of the presence of positive APT and their correlation with elevated levels 
of serum specific IgE and/or the presence of positive Skin Prick Tests (SPT) in children with 
AD up to 3 years of age. 
 
Methods 
Children eligible for inclusion were submitted to a careful history, the APT and 
measurement of serum specific IgE. In children older than 1 year of age additional SPT 
were performed. Investigated allergens included dog dander, cat dander and house dust 
mite.   
 
Results 
We included 135 children, with an age distribution ranging from 5 to 35 months. 
There were 51 girls and 84 boys. Positive APT reactions were found in 12.5% to 25% of 
patients. Immediate type, urticarial reactions were seen in 13% to 27% of positive APT 
reactions. The κ-tests showed statistically significant agreement between the different 
pairs of APT, serum specific IgE and SPT, although the strength of agreement varied 
between fair and substantial.  
 
Conclusion 
We found a substantial number of clear-cut positive APT reactions, with a relatively 
high percentage of urticarial reactions. We would like to prompt increased interest in the 
immediate type, urticarial reactions in the APT, especially in children. 
 
 
 
 
Atopy Patch Test with aeroallergens  52-134 
Introduction 
Sensitization to aeroallergens, commonly associated with direct type, IgE mediated 
allergy, is a common finding in both pediatric and adults patients with atopic dermatitis 
(AD). The exact role of this sensitization in the pathogenesis of AD remains controversial. 
There does seem to be a subgroup of patients with AD where contact with aeroallergens, 
such as house dust mite or grass pollen, is capable of worsening eczematous skin lesions.1 
Adequate avoidance measures may be helpful in controlling AD in these patients, although 
results from clinical trails are contra dictionary.2-4   
Additional evidence for a possible role of aeroallergens in the pathogenesis of AD is 
found in the fact that epicutaneous application of these allergens can elicit delayed type, 
eczematous skin reactions in patients with AD.5,6 This so-called Atopy Patch Test (APT) was 
first described in detail in 1982 and has been the focus of increased research interest over 
the last 10-15 years.7 The APT is currently widely accepted as an in vivo model of AD.8 
However, differences in methodology and the lack of a golden standard for the presence of 
a relevant sensitization to aeroallergens in AD are two major obstacles in the development 
of the APT as an addition to our allergologic work-up in patients with AD.7,9 
Most of the current clinical data on the APT with aeroallergens is based on adult 
patient populations and pediatric data is scarce. We initiated a prospective clinical study 
in children with AD up to 3 years age, to evaluate the presence of positive APT reactions 
and their correlation with elevated levels of serum specific IgE and/or the presence of 
positive Skin Prick Test (SPT) reactions.  
 
Materials and Methods 
The study was performed on the pediatric dermatology out-patient clinic of the 
Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands. Children below the 
age of 3 years with AD and an indication for an allergologic work-up, were eligible for 
inclusion. AD was defined by the criteria of Williams et al.10 Indications for an allergologic 
work-up consisted of refractory skin disease or suspected allergy to aero- or food allergens 
due to reported reactions after exposure or pre-existing diets. The inclusion period lasted 
2 years and 10 months. All patients were subjected to a careful history of possible allergic 
symptoms, combined with measurement of serum specific IgE and the APT. Additional Skin 
Prick Test (SPT) were only performed in children older than 1 year of age. Investigated 
allergens included dog dander, cat dander and house dust mite. Allergens for the SPT and 
APT were obtained from ALK-Abello and consisted of aqueous solutions with an allergen 
concentration of 10.000 PNU. Severity of AD at the time of the skin tests was measured 
using the objective SCORAD.11 
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Atopy Patch Test 
APT were performed on the unabraded skin of the back using normal (8 mm) Finn-
chambers on scanpor®. The buffer solution was tested as a negative control. After 20-30 
minutes the test areas were examined to exclude urticarial weal and flare reactions, in 
which case the skin test would be removed. Subsequently the test chambers were covered 
with fixomull®, to prevent them from shifting. After 48 hours the test chambers were 
removed. Evaluation of the skin tests took place after 48 and 72 hours, using the guidelines 
described by the European Taskforce on Atopic Dermatitis (ETFAD).12 Clear-cut reactions of 
2+ or more were regarded as positive. Urticarial reactions were also included as positive, 
immediate type APT reactions. 
 
Specific IgE     
Blood was drawn from each patient. Allergen-specific IgE was measured in serum with 
the CAP system (Pharmacia, Woerden, The Netherlands) according to the manufacturer's 
instructions. Only levels of 0,70 U/l, or above were regarded as positive. 
 
Skin Prick Test 
A drop of the solution was applied on the volar surface of forearm, after which a 
lancet was used to penetrate the skin through the drop. Histamine was tested as a positive 
control. The results were evaluated by measuring the mean diameter of the wheal reaction 
after 15 and 30 minutes. A positive reaction consisted of a wheal, which had a mean 
diameter of at least 3 mm and was at least half the diameter of the positive control. 
 
Ethical aspects and statistical analysis 
The study was approved by the Medical Ethics Committee of the Erasmus MC, 
Rotterdam, The Netherlands. The parents of all patients signed informed consent. The 
statistical analysis was performed using SPSS version 11.0. Statistical analysis was 
performed in patients with complete data necessary for the calculations. Because of 
missing test results in some patients the n-value varies between statistical calculations. 
There was no suspicion that missing data occurred selectively and we could not detect a 
bias in patient characteristics such as age, sex or severity of AD. The kappa (κ) statistic 
was used for quantifying and testing agreement between the various test scores. The 
strength of agreement is interpreted as described by Landis and Koch.13  
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Results 
One hundred and forty eight children were eligible for inclusion. We experienced 13 
dropouts due to active skin disease on the test areas (n=8), very strong positive 
dermography (n=1), multiple positive APT reactions, including the negative control (angry 
back, n=3) and 1 child who developed fever based on an airway infection during the test 
week. This left 135 children included, with an age distribution from 5 to 35 months and a 
mean age of 20 months with a standard deviation of 9 months. The mean objective 
SCORAD score was 13.6 with a standard deviation of 8.3. There were 51 (38%) girls and 84 
(62,2%) boys. SPT were only performed in children above the age of 1 year (n=102/135). 
 
 
 APT positive APT negative 
 Freq. Perc. Freq. Perc. 
Dog 
(n=120) 
15 12.5% 105 87.5% 
HDM 
(n=122) 
30 25% 92 75% 
Cat 
(n=124) 
27 22% 97 78% 
 
Table 1 
Frequency and percentages of positive and negative atopy patch test (APT) results. Results are shown for the 3 
different aeroallergens: dog dander, house dust mite (HDM) and cat dander. 
 
 
Table 1 lists the number and percentages of positive and negative APT results for the 
3 different aero-allergens. The majority of positive APT reactions consisted of classical 
delayed type eczematous reactions. However, immediate type, urticarial reactions were 
seen in 4/15 (27%) of the tests with dog dander, 4/30 (13%) of the tests with HDM and 6/27 
(22%) of the tests with cat dander. All patients with immediate type, urticarial reactions 
showed elevated levels of specific IgE and/or a positive SPT reaction.   
 
 
Number of 
allergens 
APT positive 
(n=116) 
IgE positive 
(n=123) 
SPT positive 
(n=104) 
0 70 (60.3%) 72 (58.5%) 64 (61.5%) 
1 28 (24.1%) 22 (17.9%) 17 (16.3%) 
2 14 (12.1%) 23 (18.7%) 18 (17.3%) 
3 4 (3.4%) 6 (4.9%) 5 (4.8%) 
 
Table 2 
Frequency and percentages of patients with positive reactions to 0,1,2 or 3 of the aeroallergens in respectively 
the atopy patch test (APT), serum specific IgE measurement or skin prick test (SPT). 
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Sensitization to more than one allergen was found in the APT as well as in 
measurement of specific IgE and the SPT. Details are listed in table 2. All patients with 
more than 1 positive APT reaction showed consistency in the type of APT reaction. They 
either had immediate type urticarial reactions or delayed type eczematous reactions. We 
did not find any patients with both reaction types.  
 
 N Strength of 
agreement 
κ-value p-value 
 
APT vs. IgE     
Dog 115 Fair 0.27  0.005 
HDM 119 Fair 0.38 < 0.0005 
Cat 120 Fair 0.38 < 0.0005 
APT vs. SPT     
Dog  93 Moderate 0.53 < 0.0005 
HDM 95 Fair 0.31 0.003 
Cat 97 Fair 0.39 < 0.0005 
SPT vs. IgE     
Dog 98 Moderate 0.5 < 0.0005 
HDM 101 Substantial 0.77 < 0.0005 
Cat 99 Moderate 0.57 < 0.0005 
 
Table 3 
Agreement between the atopy patch test (APT), serum specific IgE measurement and skin prick test (SPT) as 
was calculated using the kappa-test.  Results are shown for the 3 different aeroallergens dog dander, house 
dust mite (HDM) and cat dander. 
 
The agreement between different tests is detailed in table 3. The κ-tests showed 
statistically significant agreement between all three pairs of tests, although the strength 
of agreement varied between fair and substantial. We did not find any statistically 
significant impact on the data described above by either sex or age. 
 
Discussion 
Our study was performed using dog dander, cat dander and HDM as common indoor 
aeroallergens. We found clear-cut positive APT reactions in respectively 12.5%, 22% and 
25% of our patient population. Positive APT reactions to HDM were most frequent, which is 
in concordance with earlier literature on adult patients. 6,9 The frequency of positive APT 
to HDM seem to be higher in adult patients, with reported frequencies around 40%.6,9  In 
contrast we seem be find more positive APT to cat dander in our patient population 
compared to the reported frequencies of 10% to 15% in adult patients. 6,9   
In our patient population there was a statistically significant but only fair agreement 
between the APT and the presence of specific IgE or the SPT. Positive delayed type APT 
reactions were also found in patients without specific IgE or positive SPT, suggesting that 
positive APT reactions may be facilitated by specific IgE but are not dependant on its 
presence. This is in concordance with the current understanding of the pathogenesis of the 
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APT.7,8 Unlike a recent publication from Mohrenschlager et al, we did not find any 
differences in APT, serum specific IgE and SPT reactivity between boys and girls.14 There 
were also no detectable differences between these parameters when we divided our 
patients into different age-groups. We could not find a correlation between the presence 
of positive APT reactions and the objective SCORAD at the time of the skin tests (data not 
shown). As there is no gold standard for the diagnosis of a relevant allergy to aeroallergens 
in patients with AD, we did not attempt any conclusions with regard to the clinical 
relevance of the positive APT reactions. 
We found a relatively high number (13-27%) of immediate type, urticarial APT 
reactions in our patient population. These urticarial reactions were only found in patients 
with elevated serum levels of specific IgE and/or positive SPT’s against the allergen 
tested. Several test sites with urticarial reactions showed clear-cut delayed type, 
eczematous reactions after 48 and 72 hours, even though the skin test itself was removed 
after 20-30 minutes [personal observation]. Our relatively young patient population may be 
largely responsible for the relatively high percentage of urticarial reactions.15 One 
hypothesis could be that allergens are able to penetrate the epidermis of young children 
with AD more readily than in adults with AD. However, we believe there might also be an 
underreporting of immediate type, urticarial APT reactions in the current literature.  
Unfortunately, as is often the case in studies on the APT, our study methodology is 
not completely comparable to the above cited adult studies. Next to the age difference of 
the patient populations, the most obvious difference is in the allergen preparations that 
were used. From a practical point of view we chose to use the same aqueous allergen 
solutions for the SPT as well as the APT, whereas petrolatum based allergen preparations 
were used in most recent adult studies. Based on current knowledge these petrolatum 
based preparations are preferable for further standardization of the APT.8 Despite this 
reservation we believe the data described above adds valuable information to our 
currently knowledge of the APT with aeroallergens in children.  
In conclusion we found a substantial number of clear-cut positive APT reactions to 
three common aeroallergens, with a relatively high percentage of urticarial reactions, in 
our patient population of young children with AD. Although the APT seems promising as a 
diagnostic and possibly even prognostic skin test, its clinical value still appears limited at 
the moment.8,16 Further studies aimed at standardization, reproducibility and clinical 
validation in children as well as adults are needed before the APT with aeroallergens can 
be used in routine daily clinical practice.8 For future use we would like to prompt 
increased interest in the immediate type urticarial reactions in the APT, especially in 
children. 
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Elevated levels of plasma MMP-9 in patients with atopic 
dermatitis: a pilot study 
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A.P. Oranje 
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Matrix Metalloproteinase (MMP)-9 has been shown to play a role in the infiltration of 
inflammatory cells in different tissues. It is thus part of the pathogenesis of many 
inflammatory diseases, including asthma and allergic rhinitis/conjunctivitis. We compared 
plasma MMP-9 levels of 20 patients with atopic dermatitis (AD) to that of 17 control 
subjects. Additional outcome parameters consisted of the modified-objective SCORAD and 
the Three Item Severity score (TIS) in patients, peripheral blood leukocytes and eosinophils 
in both groups. Plasma MMP-9 levels were found to be significantly higher in patients 
compared to controls, supporting a role of MMP-9 in the pathogenesis of AD.  
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Introduction 
Matrix metalloproteinases (MMPs) form a group of zinc-dependent enzymes, which 
are capable of hydrolysing protein structures in the extra-cellular matrix (ECM) of tissues, 
thus playing a role in invasive tumour growth, tissue remodelling and infiltration of 
inflammatory cells in tissues.1 Through cleavage they also play a role in shedding of cell 
membrane associated proteins and activation of pro-enzymes, thus being integrated in the 
inter-cellular signalling pathways.1 MMP activity is regulated by endogenous tissue 
inhibitors of metalloproteinases (TIMPs).  
Various studies suggest that MMP-9 plays a role in the formation of the allergic 
inflammation as seen in the lungs and nasal mucosa of patients with asthma and allergic 
rhinitis.2,3 In vivo studies have also reported an increased expression of MMP-9 in human 
skin samples of positive patch tests as well as positive atopy patch tests.4,5 Based on this 
we hypothesised that MMP-9 could be important in the pathogenesis of atopic dermatitis 
(AD). 
 
Report 
The study was approved by the Ethical Committee of the Erasmus MC and all 
participants signed informed consent. Twenty patients with AD (male: female =11:9) and 
17 healthy, non-atopic controls (male: female =4:13) were included. AD was defined using 
the criteria as described by Williams et al.6 No systemic or phototherapy was allowed for 
four weeks prior to inclusion. Topical treatment consisted of emollients and once daily 
topical corticosteroids if necessary. The severity of skin lesions was assessed using the 
modified-objective SCORAD and Three Item Severity score (TIS).7,8  MMP-9 was determined 
in plasma, collected from Li-heparin tubes. Plasma samples were stored at -20 degree 
Celsius. Human MMP-9 was determined with an Elisa obtained from R&D systems 
(Abingdon, United Kingdom), according to the manufacturers’ instructions. This Elisa 
(product code DMP900) measures total MMP-9, composed of active as well as pro-MMP-9. 
Allergen-specific IgE against house dust mite, grass and cat dander was measured in serum 
with the CAP system (Pharmacia, Woerden, The Netherlands) according to the 
manufacturer's instructions. The absolute amounts of leukocytes and eosinophils were 
determined with the Sysmex XE-2100 electronic cell counter (Goffin Meyvis, Etten-Leur, 
The Netherlands). The statistical analysis was performed using SPSS 11.0. Because of the 
non-symmetric distributions of the variables involved, we used nonparametric statistical 
tests: the Mann-Whitney test for comparison of the two groups and the Spearman rank 
correlation test for the relationships between the variables.  
 
MMP-9 in patients with AD  63-134 
Twelve of 20 patients had a history of asthma. Only 2 of these 12 patients had active 
disease, controlled with corticosteroids via inhalation. None of 16 patients with a history 
of allergic rhinitis/conjunctivitis had active disease or used any medication. Seventeen 
patients showed elevated levels of specific IgE (> 0.70 IE/ml) against one or more of the 
aero-allergens tested. The mean modified objective SCORAD in the patient group was 27.1 
(13-46). Non-parametric analysis, using the Mann-Whitney test, showed significantly higher 
levels of plasma MMP-9 (p<0.0005) in the patient group as compared to the control group 
(table 1).  
 
 
Patients Controls  
Median Minimum Maximum Median Minimum Maximum 
P 
(2-sided) 
MMP9 (ng/ml) 
N=20 vs. N=17 
264.78 64 917 31.27 11 131 <0.0005 
Leucocytes (109/l) 
N=20 vs. N=17 
6.05 3.40 11.30 6.57 5.10 9.38 0.156 
Eosinophils (109/l) 
N=17 vs. N=17 
0.39 0.07 1.53 0.09 0.04 0.34 <0.0005 
Table 1 
Non-parametric analysis, using the Mann-Whitney test, of plasma MMP9 values, leukocyte counts and 
eosinophilic granulocyte counts in peripheral blood of patients with AD versus control subjects. 
 
The absolute amounts of leukocytes were not significantly different between both 
groups. Using Spearman’s rank correlation test there was a significant correlation between 
plasma MMP-9 and the absolute amount of leukocytes in patients (r=0.48, p=0.033), but 
not in controls (r=0.076, p=0.772) (fig. 1). Although there were a significantly higher 
number of eosinophils present in the peripheral blood of patients compared to controls, 
there was no significant correlation with plasma MMP-9 levels in either group (respectively 
r=0.052, p=0.844 and r=-0.137, p=0.601). No statistically significant correlation could be 
found between plasma MMP-9 and the modified-objective SCORAD (r=0.005, p=0.985) or 
the TIS (r=-0.28, p=0.912).  
This study shows significantly increased levels of MMP-9 in plasma of patients with AD 
as compared to healthy controls, suggesting a role for  MMP-9 in the pathogenesis of AD. A 
possible explanation for the correlation between the absolute amount of leukocytes in 
peripheral blood and plasma MMP-9 in our patient group, might be that in active AD the 
number of peripheral blood leukocytes reflects the intensity of skin inflammation and thus 
the level of plasma MMP-9. Peripheral blood MMP-9 levels in asthma and chronic urticaria 
have been shown to correlate with disease severity.9 However, in our patients we could 
not find a significant correlation between plasma MMP-9 levels and the modified-objective 
SCORAD or TIS, as markers of disease severity.  
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Fig 1 
Plasma MMP-9 versus absolute amount of leukocytes in patients and healthy control subjects. Non-parametric 
analysis, using Spearman’s rank correlation test, showed a significant correlation in the patient group (r=0,48; 
p=0,033), while no significant correlation was observed in the control group. 
 
 
Although our patients and the control group are not perfectly matched with regard to 
age and especially gender, we believe this does not affect our findings. Both parameters 
were previously found to have no effect on circulating MMP-9 in healthy controls.10 In 
addition we also found plasma MMP-9 values in our control group, which are comparable to 
values found by Kessel et al, who used a very similar methodology.9 Only  two of our 
patients had active airway disease, adequately controlled with corticosteroids via 
inhalation. For this pilot study we did not exclude them in our results, although a possible 
influence of the airway disease and/or the medication cannot be excluded. Further, larger 
studies are needed to evaluate plasma MMP-9 levels in AD, including stratification for 
concomitant asthma and allergic rhinitis. 
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Background 
"Wet-wrap" dressings with diluted corticosteroids form an alternative treatment in 
patients with refractory atopic dermatitis 
 
Objective 
To evaluate a standardized treatment, using “wet-wrap” dressings with diluted 
corticosteroids, in patients with refractory atopic dermatitis. 
 
Methods 
Results of treatment, complications and possible side effects were evaluated in 14 
children and 12 adults. 
 
Results 
Skin lesions improved dramatically during 1 week of in-patient treatment. A 
significant decrease in early-morning serum cortisol levels was measured. Levels below the 
normal range were only observed after 1 week in 2 adults and on day 4 in 3 children. 
Suppression of the hypothalamic-pituitary-adrenal cortex-axis in 1 adult and a new 
exacerbation of atopic dermatitis in 2 children and 3 adults complicated long-term 
treatment at home. Additional complications included folliculitis, a Pseudomonas 
aeroginosa infection, secondary bacterial infection and refractory skin lesions between 
bandages. 
 
Conclusion 
“Wet-wrap” dressings and diluted corticosteroids form an effective treatment in 
patients with refractory atopic dermatitis.  
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Introduction 
Emollient and topical corticosteroids are the mainstay in the treatment of atopic 
dermatitis. Unfortunately there are patients who are unresponsive to conventional 
therapy. Current intervention treatments for patients with refractory atopic dermatitis 
(AD) consist of cyclosporine A, systemic corticosteroids, phototherapy and photo-
chemotherapy. More experimental treatments, such as recombinant interferon γ and high 
doses of  immunoglobulines intravenously, are also available. Each one of these treatments 
has its own drawbacks and side effects, limiting its use in daily practice. "Wet-wrap" 
dressings and diluted corticosteroids form a recently developed alternative for patients 
with severe and refractory AD. Long-term treatment at home seems feasible. We studied 
the results of a standardized treatment, using "wet-wrap" dressings and corticosteroids in 
patients with refractory AD.  
 
Patients and Methods  
Adults and children with refractory AD, as defined by Hanifin and Rajka and Sampson 
and Williams et al., respectively, who visited our (pediatric) dermatology out-patient clinic 
between March 1999 and March 2000, were eligible for treatment according to a 
standardized protocol. 
 
In-patient treatment 
Treatment was started on day 1. Details are listed in table 1. In short, patients 
bathed for 5-10 minutes in lukewarm water, followed by application of diluted fluticasone 
propionate 0.05% (FP) cream on the entire body. Then a wet layer of tubular bandage was 
applied, followed by a second dry layer. The first layer was re-wetted every 2-3 hours. On 
the facial skin a 5% dilution of FP cream was used. A side-to-side treatment was started on 
the body, consisting of a 10% and a 25% dilution in adults and a 5% versus a 10% dilution in 
children. The entire procedure was repeated once daily, during a period of 1 week. 
 
Follow-up  
After patients were discharged from the hospital, the treatment was continued at 
home for four consecutive days. Diluted FP cream was now only used on clinically involved 
skin, applying emollient on uninvolved skin. In the next three days of the week, only 
emollient was applied to the skin. Depending on the severity of the symptoms, the number 
of days with the "wet-wrap" treatment was adjusted, with a maximum of 5 days a week. 
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1. 
 
Chose the appropriate width of the tubular bandages and cut these to size to fit the arms, 
legs and trunk. Cut a facial mask if necessary. 
 
2. Apply the appropriate dilution of fluticasone propionate 0,05% (FP) cream on the skin 
 
3. Wet the individual pieces of tubular bandage in lukewarm water. 
 
4. Apply the first layer of wet tubular bandage. Connect the arm and leg pieces to the trunk. 
Use the facial mask if necessary. 
 
5. Apply the second layer of dry tubular bandage. Again connect the arm and leg pieces to the 
trunk. Use the facial mask if necessary. 
 
6. Re-wet the bandages every 2 to 3 hours. 
 
7. Repeat the above mentioned procedures daily. 
 
8. After one week of treatment the diluted FP cream is only applied on the clinically involved 
skin for 3-5 consecutive days of the week. Emollient is applied on the uninvolved skin. 
Patients can perform the treatment at home. 
 
 
Table 1 
Methodology of the  “wet-wrap”  treatment using diluted fluticasone propionate 0,05% cream. (According to 
Oranje, based on the method as described by Goodyear et al.) 
 
Safety 
Early-morning cortisol levels were measured before and after 1 week of treatment to 
assess the systemic load of the topical corticosteroids. Blood samples were drawn in adults 
and children at 8:00 and 6:00 a.m., respectively. Reference values show a lower limit of 
200 nmol/l. In children, an additional value was measured on day 4. During follow-up, the 
measurements of early-morning cortisol were repeated according to protocol. Weight and 
height of the children were recorded.  
 
Disease severity 
Severity of AD was evaluated using the objective SCORAD score. This scoring system 
combines the extent of the skin lesions and the intensity of six clinical features of AD. The 
objective SCORAD was performed on day 0 as well as on day 7. During follow-up the score 
was repeated at regular intervals. 
 
Statistic analyses 
The statistic analyses was performed using SPSS 9.0. The change in objective SCORAD 
was analyzed using a paired T-test. The data of the early-morning cortisol levels were 
analyzed using the Wilcoxon’s signed rank test . Significance was defined as p<0.05% (2-
sided) 
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Results 
Fourteen children and 12 adults with refractory AD were treated according to 
protocol. The group of children included 8 girls and 6 boys, aged between 6 months and 10 
years and 1 month (average 3 years and 1 month).  The adults included 7 women and 5 
men, aged between 18 years and 61 years and 3 months (average 29 years and 11 months). 
The average follow-up lasted 17 weeks (11-41). Two adults were lost to follow-up after 1 
and 8, weeks respectively. 
 
Hospitalization 
Thirteen children and 2 adults were treated using the "wet-wrap" dressings including 
a facial mask. The remaining patients did not use a facial mask at their own request or due 
to absence of facial skin lesions. Three children and 10 adults used additional mild to 
moderate topical corticosteroids in order to treat facial or scalp lesions. Because of 
bronchitis two adults used FP 125 µg twice a day via an inhaler. For the same reason, one 
adult used 500 µg FP twice a day via an inhaler, combined with prednisone 5 mg once a 
day orally. Prednisone was discontinued during his hospitalization. 
Figure 1 
Disease severity, before and after 1 week of treatment, as reflected in the (mean) objective SCORAD (n=18). 
 
A marked improvement of skin lesions was noted in all patients. Objective SCORAD scores, 
before and after treatment, were available in 18 cases (figure 1). Using a paired T-test, a 
significant decrease of 26.78 points in the objective SCORAD was observed after 6-9 days 
(table 2). Individual analysis of the children and adults showed a decrease of 25.43 and 
27.62 points, respectively. In 1 child and 4 adults a difference was observed at day 4/5 in 
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favor of the less diluted and thus more potent concentration of FP cream (1:9 and 1:3, 
respectively). In the other 21 patients no differences between both sides were observed.  
 
 
 95% CI 
 
SCORAD 
(day 0) 
SCORAD 
(day 6-9) 
Decrease in  
SCORAD Lower value Upper value 
p-value 
(2-sided) 
Total (n=18) 42.06 15.28 26.78 21.90 31.65 <0.0005 
Children (n=11) 39.09 11.45 27.64 20.87 34.40 < 0.0005 
Adults (n=7) 46.71 21.28 25.43 16.18 34.67 < 0.0005 
 
Table 2. 
Improvement of disease severity during treatment, reflected in a significant decrease in the mean objective 
SCORAD between day 0 and day 6-9. Data are given for the group as a whole and for children and adults 
separately. The analysis was performed using a paired T-test. 
 
 
Planned early-morning cortisol levels before and after treatment were available for 
24 patients (figure 2 and 3). Using Wilcoxon’s signed rank test, a significant decrease in 
cortisol levels was observed after treatment (table 3). On individual analysis of both 
children and adults, this decrease was still significant. No children and only 2 adults 
showed cortisol levels below 200 nmol/ml at the end of treatment. Both adults used 
additional topical corticosteroids on face and scalp. One patient had been treated with the 
less diluted and more potent concentration of FP cream (1:3) after day 5 and the other one 
used FP via an inhaler. The patient using prednisone orally, had cortisol levels below 200 
nmol/ml both before and after treatment. No significant decrease was observed between 
the cortisol levels on day 1 and day 4. However, 3 children showed a temporary drop 
below200 nmol/ml, which had normalized at the end of the week, despite continuation of 
the treatment One of these children had used mild topical corticosteroids on the scalp. 
Further complications were limited to a mild localized folliculitis.  
 
 
Figure 2. 
Course of early-morning serum cortisol levels during hospitalization in 13 children. 
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Figure 3. 
Course of early-morning serum cortisol levels during hospitalization in 11 adults. 
 
 
 
 Cortisol levels day 0 
(nmol/l) 
Cortisol levels day 6-9  
(nmol/l) 
 Min. Max. Median Min. Max. Median 
Z P 
(2-sided) 
Total (n=24) 144 1159 557 <0.27 1096 335 -3.40 <0.001 
Children (n=13) 258 890 585 206 549 410 -2.41 <0.016 
Adults (n=11) 144 1159 545 <0.27 1096 312 -2.40 <0.016 
 
Table 3 
Early-morning serum cortisol levels are listed for the group as a whole and for children and adults separately. 
A significant decrease during one week of treatment was noted in all three groups. The analysis was performed 
using Wilcoxon’s signed rank test. 
 
 
Follow-up. 
Exacerbations of AD, cortisol levels below 200 nmol/ml and further complications are 
summarized in table 4. Exacerbations of AD occurred in 2 children and 3 adults. 
Interventions consisted of cyclosporine A (1), renewed hospitalization for treatment with 
tar ointment (3) and prednisone orally in 1 child with simultaneous respiratory distress. 
After the intervention, 2 patients continued and 3 patients discontinued the "wet-wrap" 
treatment at home. 
Temporary cortisol levels below 200 nmol/ml were observed in 2 children and 1 adult 
man, who used FP via an inhaler, combined with frequent episodes of prednisone orally. 
The 2 children did not use any additional corticosteroids. Their height and weight 
remained unaffected. One adult, who also used FP via an inhaler, developed a prolonged 
suppression of his hypothalamus-pituitary-adrenal cortex (HPA) axis, in combination with 
several striae on his abdomen. 
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Complications during long-term 
treatment at home 
Number 
(n=24) 
Severity of disease 
- Exacerbation AD 
 
5 
Systemic bioactivity 
- Temporary cortisol levels <200 nmol/l 
- Prolonged suppression  HPA-axis  
 
3 
1 
Further complications 
- Infectious  
- Refractory skin lesions on hips 
- Striae on abdomen 
- Deviated growth 
 
9 
1 
1 
1 
 
Table 4 
The complications occurring during long-term treatment at home, divided in three categories. Two patients 
were lost to follow-up after 1 and 8 weeks, respectively. HPA-axis = Hypothalamus-Pituitary-Adrenal cortex-
axis 
 
 
Further complications consisted of localized folliculitis (4), secondary impetigo (2), a 
localized Pseudomonas aeroginosa infection, cellulitis of the left cheek in a patient 
without a facial mask and a purulent conjunctivitis in a patient with a facial mask. The last 
patient reported frequent episodes of conjunctivitis in the past. One child showed 
refractory skin lesions on his hips and buttocks and one child showed a deviation in his 
growth, without any abnormal cortisol levels. Retrospectively the growth deviation had 
started before the start of the "wet-wrap" treatment and was the result of a low food 
intake. His eating habits improved, with help from our dietician. Subsequently, he caught 
up with his estimated growth curve, despite continuation of treatment.  
 
 
Discussion 
In 1991, Goodyear et. al. described a highly effective "wet-wrap" treatment with 
diluted topical corticosteroids in children with severe erythrodermic atopic dermatitis.[10] 
In our department we established a modified protocol using a dilution of FP cream (table 
1).[11,12] FP cream is a potent corticosteroid with an improved benefit/risk ratio.[18,19] 
The use of this protocol in the treatment of  patients with refractory AD has been shown to 
be very effective.[11,12] The greatest improvement in AD occurs in the first week of 
treatment.[12] The use of a less potent dilution of FP cream shows a comparable high 
efficacy, with a lower risk of systemic bioactivity.[12] The mode of action of the "wet-
wrap" treatment is a combination of reduction of pruritis and inflammation by cooling of 
the skin, increased penetration of topical corticosteroids by creating an occlusive and 
moist environment and protection of the skin against scratching.  
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The current retrospective study confirms the efficacy and safety of this standardized 
treatment in patients with refractory AD. Thirteen children and 8 adults continued 
treatment with the less potent dilution of FP after day 4-5 (1:19 and 1:9 respectively). 
Despite a significant decrease in early-morning cortisol levels in both groups, only 2 adults 
developed a cortisol level below 200 nmol/l during hospitalization. One of them developed 
a prolonged suppression of his HPA-axis during follow-up. The low cortisol levels may be 
explained by the use of more potent dilutions of FP cream after day 4-5, the use of 
additional topical or inhaled corticosteroids and an increased individual sensitivity to 
corticosteroids. The temporarily decreased cortisol levels below 200 nmol/l in 3 children 
halfway treatment were remarkable. A possible explanation is provided by a repair of the 
barrier function of the skin during treatment, causing a decreased penetration at the end 
of the treatment.   
The use of early-morning serum cortisol levels as a parameter of systemic side 
effects, is an easy but rather insensitive method due to a large inter- and intra-individual 
variability.[20] An improved sensitivity and specificity might be achieved using early-
morning cortisol/creatinine ratios in urine or cortisol levels in saliva. [21,22] These 
methods are also less invasive, which is an additional advantage, especially in children. 
Folliculitis is a well-known side effect of the "wet-wrap" treatment, probably due to 
its occlusive effect.[12] Use of diluted corticosteroids may suppress the process, however, 
also aggravate it in some cases. The localized Pseudomonas aeroginosa infection was 
remarkable. Possibly, the moist environment under the bandages was involved. The water 
sprayer, which was used to re-wet the bandages, may have acted as a source of infection, 
due to insufficient cleaning. Patients with AD are at risk for secondary bacterial infections 
due to a decreased skin barrier among other things. It is possible that the "wet-wrap" 
treatment with diluted corticosteroids increases this risk, but to what extent is unknown. 
Obviously the "wet-wrap" treatment should be stopped during episodes of secondary 
bacterial infections. Refractory skin lesions on the connection between two bandages are a 
known problem. A connection between the treatment and the occurrence of cellulitis, 
purulent conjunctivitis and the growth deviation is very unlikely.   
 
 
Conclusion 
The "wet-wrap" treatment with diluted corticosteroids, as described above, is a very 
effective treatment in patients with severe and refractory AD. The most important side 
effect consists of a (temporary) suppression of the HPA-axis in a minority of the patients. 
The use of a less potent dilution of FP cream diminishes this risk, while maintaining a good 
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efficacy. In children a 1:19 dilution of FP cream is advised. Long-term treatment at home 
is feasible when patients (and parents) are motivated and provided with adequate 
instruction and guidance. A day-care center, with dermatologically qualified nurses, 
provides an excellent setting for the follow-up of these patients. 
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Efficacy and safety of "wet-wrap" dressings as an 
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literature 
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Background  
During the last 2 decades wet-wrap treatment (WWT) has been advocated as a 
relatively safe and effective treatment modality in children with severe and/or refractory 
atopic dermatitis (AD). Unfortunately, there are still many unsolved issues concerning the 
use of wet-wrap dressings in patients with AD.  
 
Objectives 
To make an inventory of the different methodologies and to evaluate the currently 
available evidence for the use of WWT as an intervention treatment in children with severe 
and/or refractory AD 
Methods 
We performed a search of the literature via the online PubMed database. Reference 
lists from relevant articles were scanned for additional publications. Publications 
describing a treatment modality for children with severe and/or refractory AD, which 
included the application of wet dressings, were collected and evaluated using the 
guidelines of the NHS Centre for Reviews and Dissemination, University of York (CRD). 
 
Results 
Twenty-four publications were included for evaluation. Eleven of the publications 
detailed original clinical studies (study design level 2-4), while 13 revealed expert’s 
opinions (study design level 5). Evidence levels did not exceed level 4 
 
Conclusions 
Large prospective studies evaluating the efficacy and safety profile of WWT are 
lacking. We were able to formulate the following conclusions with a grade C of 
recommendation. (i) WWT using cream or ointment and a double layer of cotton bandages 
with a moist first layer and a dry second layer, is an efficacious short-term intervention 
treatment in children with severe and/or refractory AD. (ii) The use of wet-wrap dressings 
with diluted topical corticosteroids is a more efficacious short-term intervention treatment 
in children with severe and/or refractory AD than wet-wrap dressings with emollients only. 
(iii) The use of wet-wrap dressings with diluted topical corticosteroids for up to 14 days is 
a safe intervention treatment in children with severe and/or refractory AD, with 
temporary systemic bioactivity of the corticosteroids as the only reported serious side 
effect. (iv) Lowering the absolute amount of applied topical corticosteroid to once daily 
application and further dilution of the product can reduce the risk of systemic bioactivity. 
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Introduction 
The treatment of children with atopic dermatitis (AD) can be challenging for medical 
professionals as well as patients and their parents. Conventional treatment, consisting of 
emollients and topical corticosteroids, is not always sufficient, even when combined with 
appropriate information and guidance. Recently, topical calcineurin inhibitors have been 
introduced as an alternative treatment option in children older than 2 years. Although they 
are a welcome addition to our therapeutic arsenal, they are not more effective than 
potent topical corticosteroids.1   
Known intervention treatments for severe and/or refractory AD include systemic 
corticosteroids, cyclosporine A, azathioprine and photo(chemo)therapy.2,3,4,5 All of these 
interventions have their potential side effects and (relative) contraindications, especially 
in children. During the last two decades wet-wrap treatment (WWT) has been advocated as 
a relatively safe and effective treatment modality in children with severe and/or 
refractory AD. Despite several publications from different research groups, there are still 
many unsolved issues concerning the use of wet-wrap dressings in the treatment of AD. We 
performed a review of the literature in order to make an inventory of the different 
methodologies and to evaluate the currently available evidence for the use of WWT as an 
intervention treatment in children with severe and/or refractory AD. 
 
Review questions 
The following review questions were drawn up based on a population of children with 
severe and/or refractory AD. WWT was defined as a treatment modality using a double 
layer of tubular bandages or gauze, with a moist first layer and a dry second layer. 
1. In which ways does the methodology of the treatment with wet-wrap dressings differ 
between the publications? 
2. Is the use of wet-wrap dressings an efficacious intervention treatment modality? 
3. Is the use of wet-wrap dressings with (diluted) topical corticosteroids more 
efficacious than the use of wet-wrap dressings with emollients or emollients in 
combination with antiseptics? 
4. Is the use of wet-wrap dressings with (diluted) topical corticosteroids a safe 
intervention treatment modality? 
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Methods 
We performed a search of the literature via the online PubMed database. Different 
search strings were entered using the keywords “wet-wrap” and “wet dressings” alone or 
in combination with “atopic dermatitis” and “atopic eczema”. Reference lists from 
relevant articles were scanned for additional publications. 
Publications describing a treatment modality for children with severe and/or 
refractory atopic dermatitis, which included the application of wet dressings, were 
collected.  The publications were then divided according to primary study design hierarchy 
as described in the guidelines of the Centre for Reviews and Dissemination, University of 
York (CRD, level 1 to 5).6 With regard to the review questions concerning effectiveness, we 
also assessed the quality of the publications and assigned a level of evidence (level 1 to 5), 
which lead to grades of recommendation attached to the conclusions. 
 
Results 
Twenty-five publications were collected after our search was performed. Twenty-
four of these publications were included for evaluation. Eleven of the included 
publications detailed original clinical studies (study design level 2-4),7-17 while 13 revealed 
expert’s opinions (study design level 5).18-30 One original clinical study was performed in 
infants with moderate atopic dermatitis and was thus excluded from the results section.31 
Because of the unique nature of this last study, it will be discussed briefly further on. The 
publications with expert’s opinions showed some overlap in content, caused by multiple 
publications from the same author or institution.   
 
In which ways does the methodology of the treatment with wet-wrap dressings differ 
between the publications?  
The methodology of WWT, as described in the 24 publications, differs with regard to 
nine key points, as is summarized in table 1. If we only look at the clinical studies, we find 
that 10 of the 11 first authors advocate the application of either cream (n=6) or ointment 
(n=4) directly on the skin instead of soaking the first layer of bandages in warmed up 
cream (n=1). When mentioned, the primary reason for direct skin application is that it 
would be less time consuming. (Re)wetting of the first layer of bandages was carried out 
with plain water in 9 out of these 10 studies and was combined with an aqueous solution of 
chlorhexidine in one. With the exception of one publication, describing a facial WWT with 
plain gauze, all the clinical studies reported the use of elasticated tubular cotton 
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bandages. In 9 studies they used Tubifast, while in one study they used either Tubifast 
or Tubigrip, depending on the preference of the patients and their parents. Four of the 
11 studies reported a WWT including a facial mask. 
 
Topical product Cream or ointment as emollients, (diluted) topical corticosteroids or a 
combination of both. 
 
Type of bandages Double layer of cotton cloth, plain cotton gauze or elasticized cotton 
tubular bandages (Tubigrip® or Tubifast®). A second layer of flannel 
instead of cotton was also reported. 
Application technique 
of topical product 
The topical product is applied directly on the skin or is warmed up and 
used to soak the first layer of bandages, which is then applied onto the 
skin. 
Application frequency 
of topical product 
Once to thrice daily.  
 
 
(Re)wetting of the 
first layer of bandages 
Once, twice, thrice or every 2-3 hours daily.  Water is most commonly 
used but an antiseptic solution and soaking of the first layer in heated 
cream have been reported 
Bandages left in situ 3, 6-8, 12 or 24 hours per day 
 
Area treated Only the extremities, the trunk and the extremities, only the face, or 
the entire body  
 
Duration of treatment Intervention treatment of 2 to 14 days. 
 
Location of treatment Hospitalization or out-patient treatment 
 
 
Table 1 
Possible differences in the methodology of wet-wrap treatment 
 
 
Is the use of wet-wrap dressings an efficacious intervention treatment modality? 
Ten out of 11 included original clinical studies reported data on the efficacy of a 
WWT in children with severe and/or refractory AD. They all used a WWT consisting of a 
double layer of tubular bandages or gauze, with a wetted first layer and a dry second 
layer. Cream or ointment was applied directly on the skin in 9 studies and soaked into the 
first layer of bandages in the study of Goodyear et al.9 The details concerning the patient 
population, topical products, application frequency, duration of treatment and outcome 
parameters of efficacy are listed in table 2.   
“Wet-wrap” treatment in AD: a critical review 83-134 
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Efficacy was scored using different clinical scoring systems. The SCORAD index was 
used in one publication. This system combines the extent (A) and intensity (B) of skin 
lesions with subjective scores on itch and sleeplessness (C).32 Three publications used the 
modified objective SCORAD (A and B) and 1 publication used a regional SCORAD (B). 
Unclassified clinical scoring systems (CCS) were used in 2 and investigator global 
assessments (IGA) in 3 studies. Additional parameters included transepidermal water loss 
(TEWL) measurement, parental questionnaires aimed at the subjective assessment of the 
impact of AD on daily life and similar patient or parent assessments obtained during an 
interview.  
Although the methodology varied with regard to several other previously mentioned 
key points, all studies reported a successful intervention treatment of 2-14 days, with an 
improvement of AD skin lesions (evidence level 4). This is in concordance with the stated 
expert’s opinions and our own experiences, which describe WWT as a successful 
intervention treatment in children with severe and/or refractory AD (evidence level 5).  
 
Is the use of wet-wrap dressings with (diluted) topical corticosteroids more efficacious 
than the use of wet-wrap dressings with emollients or emollients in combination with 
antiseptics? 
Several experts describe a successful WWT with emollients only, usually in patients 
with milder but still extensive skin disease.18,19,20,22,28,29  However, WWT using (diluted) 
topical corticosteroids is generally regarded as being more efficacious, which is in 
concordance with our own experiences (evidence level 5). The available data from the 2  
clinical studies detailed below supports this notion, although the number of included 
patients is small (evidence level 4).  
Schnopp et al reported a controlled trial in which they performed a WWT on both 
arms of 20 patients.14 They used mometasone furoate 0.1% (MF) ointment on one side and 
its vehicle on the other side. After 3 and 5 days the severity of AD lesions improved on 
both sides, with a significantly better improvement of the regional SCORAD scores on the 
MF treated sides compared to the vehicle treated sides.  
Wolkerstorfer et al performed a pilot study on the influence of corticosteroid dilution 
on the efficacy of WWT.17 They report an impressive improvement in the modified 
objective SCORAD scores after 1 week of treatment, irrespective of the dilution of 
fluticasone propionate 0,05% (FP) cream used (5%, 10% or 25%). Two patients were treated 
with the same methodology, using emollients instead of diluted FP cream. They only 
showed a minor improvement. The improvement in objective SCORAD scores in their study 
was related to the absolute amount of applied corticosteroid per m2 body surface. This 
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curve levelled out at approximately 800 µg/m2 body surface, above which efficacy hardly 
increased further.  
No statements can currently be made on the efficacy of a WWT using emollients and 
antiseptics as compared with (diluted) corticosteroids or emollients alone. Abeck et al 
published a clinical study detailing a WWT with application of emollients thrice daily 
combined with chlorhexidine 0.5% solution twice daily to wet the first layer of bandages.6 
Their treatment was efficacious, showing an improvement of the SCORAD index from 56.9 
(±5.6) to 32.4 (±1.5) after 3 days of treatment (evidence level 4). However, a direct 
comparison of these results with studies using (diluted) corticosteroids or emollients alone 
is not possible due to differences in methodology and outcome measures.  
 
Is the use of wet-wrap dressings with diluted topical corticosteroids a safe intervention 
treatment modality? 
When using wet-wrap dressings with (diluted) topical corticosteroids the primary 
safety concern is systemic bioactivity of the corticosteroids. Six of the clinical studies 
included safety parameters intended to detect systemic bioactivity, as detailed in table 3. 
Measurements of early morning serum cortisol (EMSC) and urinary cortisol/creatinine 
ratio (UCCR) before and after treatment have shown a temporary decrease of the values 
during treatment periods of 2-14 days (evidence level 4). Goodyear et al found profound 
decreases of EMSC levels below the detection level in all their patients after 2-5 days of 
treatment.9 Two weeks after completion of the active therapy their values had normalised. 
The publications of Wolkerstorfer et al and Devillers et al showed that the risk of EMSC 
levels dropping below the lower reference value could be decreased by once daily 
application and further dilution of the topical corticosteroids to 10% or even 5% of their 
original strength (evidence level 4). 8,17 Prolonged suppression of the hypothalamus-
pituitary-adrenal-cortex axis has not been reported after short-term intervention 
treatment. Devillers et al reported one adult patient with a prolonged suppression after a 
long-term treatment at home, with an average follow-up of 17 weeks (11-41).8 He also 
used concomitant corticosteroids via inhalation. One of the most important clinical 
symptoms of systemic bioactivity of corticosteroids in children is growth retardation. 
McGowan et al looked at short-term growth and bone turnover during wet-wrap treatment 
with diluted corticosteroids in 8 children with a median age of 5.1 (3.3-8.8) years.11 They 
used knemometry to measure lower leg length growth rate and urinary deoxypyridinoline 
crosslink excretion corrected for creatinine excretion to measure bone and collagen 
turnover. There were no significant differences found between the outcomes before and 
during a median treatment period of 12 (2-18) weeks.  
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Table 4 lists reported adverse events other than systemic bioactivity in both clinical 
studies and expert’s opinions. Unfortunately only 4 of the 11 clinical studies report 
percentages on some of these adverse effects.8,9,10,15  We decided to assign each event to a 
different risk factor group, stating the frequency as rare, common or frequent. The 
assignments were made on the basis of the limited available data on percentages and our 
own personal experience.  
  
 
Adverse event Occurrence 
Discomfort including chills and poor acceptance Frequent 
Folliculitis Common 
Refractory skin lesions on the areas not covered by bandages Common 
Impetigo Rare 
Cutaneous Pseudomonas aeruginosa infection Rare 
Herpetic infections Rare 
 
Table 4  
Reported complications, besides temporary systemic bioactivity, during an intervention treatment with wet-
wrap dressings and (diluted) topical corticosteroids for a maximum period of 14 days. 
 
 
Discussion 
This review confirms our initial suspicion regarding the wide variety in methodology 
with regard to WWT. Based on the available data and our own experiences we would like 
to make some general remarks with regard to future standardisation of treatment.  
Most authors, including ourselves, advocate application of cream or ointment directly on 
the skin instead of soaking the first layer of bandages in heated cream. Preparation time 
can thus be reduced, while good efficacy is maintained. Application frequencies of up to 3 
times per 24 hours have been reported during use of emollients. Using diluted topical 
corticosteroids is more efficacious than using emollients only. However, using diluted 
topical corticosteroids warrants once daily application, because of the risk of systemic 
bioactivity. Which topical corticosteroid should be used and to what degree it should be 
diluted is still uncertain. The most commonly reported products used are 10% dilutions of 
potent corticosteroids.9,10,13,15,16 The studies from Wolkerstorfer et al and Devillers et al 
confirmed a good clinical efficacy and safety of WWT using a 10% dilution of FP cream.8,17 
They also reported good results with a 5% dilution, which might indicate that further 
dilution without loss of efficacy is possible. At this moment a 10% dilution seems to provide 
adequate efficacy and safety and is a good starting point for further studies. Advocating 
the use of fluticasone propionate or mometasone furoate above other moderately potent 
corticosteroids is based on their known pharmacological properties and is another issue in 
need of further investigation.  
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In theory, all closefitting cotton bandages can be used in WWT. Tubifast elasticated 
tubular cotton bandages are currently the most commonly used. In 2003 Tubifast 
Garments were introduced onto the market. This product line includes long sleeved 
shirts, pants, socks and gloves in different paediatric sizes. They are made from similar 
material as the original Tubifast and can be washed and reused up to 20 times according 
to the manufacturer. Using the garments facilitates the treatment and may save a 
considerable amount of time during the preparation and application phase of the 
treatment. The use of a facial mask during a WWT is possible and can have good clinical 
results.8,12,16,17  However, one should always keep in mind the psychosocial consequences of 
wearing a mask and the fact that not all children and/or parents will accept their 
application. Their use should be discussed separately with patients and their parents when 
WWT is considered.  
Different strategies were reported regarding application time of the bandages, 
ranging from 3 to 24 hours a day. Longer application times are probably more efficacious, 
although there is no clear evidence to support this. In a hospital setting a 24-hour 
treatment schedule is feasible and in our opinion advisable. This is more difficult when 
patients are treated on an outpatient basis and schedules have to be incorporated into 
daily life. Intervention treatments of 2 to 14 days have been published in clinical studies. 
With use of (diluted) topical corticosteroids, we would like to advocate an intervention 
treatment with a maximum of 7 days. This period is consistent with the study of 
Wolkerstorfer et al, who reported substantial improvement during the first week of 
treatment with little further improvement in the second week, and with the strategy of 
most authors, who describe good clinical efficacy with treatment periods of up to 1 week 
(table 2). 17  
WWT, especially when combined with (diluted) topical corticosteroids, is a very 
efficacious intervention treatment in children with severe and/or refractory AD. 
Unfortunately it is also a very laborious and time-consuming treatment modality that calls 
for close supervision. Use of topical corticosteroids involves the risk of systemic bioactivity 
and the different parameters influencing this risk should be considered. Several possible 
risk factors for systemic bioactivity during WWT with diluted corticosteroids were 
suggested, including the type of corticosteroid, the dilution, twice daily versus once daily 
application, inter-individual differences between patients and the use of concomitant 
corticosteroids, for instance via inhalation.  Four of the 6 clinical studies summarized in 
table 3 propagated the use of a “new generation” topical corticosteroid, either fluticasone 
propionate or mometasone furoate. These products claim a potent local effect with 
relatively low systemic absorption, which in theory should be beneficial for further 
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reduction of systemic bioactivity during wet-wrap treatment with diluted corticosteroids. 
However, a controlled trial comparing the use of these products versus the older topical 
corticosteroids in a WWT is lacking.  
Other adverse events are usually mild and temporary but should also be considered. 
The reported discomfort is mostly due to chills after application of the first moist layer of 
bandage, warranting close attention to the temperature of the water. Induction of 
folliculitis is probably due to the occlusive effect of the treatment and may be reduced by 
using creams instead of ointments and application of the topical product in the direction of 
hair growth. Whether or not there is an increased risk of impetigo or herpetic skin 
infections is still unclear. Both events are well known complications in children with AD 
without WWT. Secondary skin infections with Pseudomonas aeruginosa appear to be rare, 
but are possibly due to the moist environment induced by the bandages. Insufficient 
cleaning of the water sprayers used to rewet the first layer of bandages may constitute a 
cause of infection. Although striae have not been reported during a wet-wrap intervention 
treatment, they were observed during a long-term intermittent treatment.8 Because 
children entering puberty are already at risk of developing striae, we consider this age 
group to have a relative contraindication against WWT.  Cost-benefit ratios of WWT were 
not included in this review, but seem to be lacking at the moment.  
We believe that WWT should be reserved for second line intervention treatment in 
patients with AD who have failed to respond to conventional treatment schedules. This is 
in concordance with a publication from Goodyear and Harper, who advocated caution in 
the use of WWT for atopic dermatitis.21 Further support is found in a recent publication 
from Beattie and Lewis-Jones, who performed a pilot study comparing a WWT with 
hydrocortisone acetate cream to the use of hydrocortisone acetate cream twice daily 
without wet-wrap dressings.31 Both patient groups consisted of children with moderate AD. 
No significant differences in clinical efficacy scores or quality of life scales were found 
between the two groups and the authors concluded that WWT should not be considered as 
a first line treatment in mild to moderate atopic dermatitis. 
This review shows an overview of the currently available evidence for the use of 
WWT as an intervention treatment in children with severe and/ or refractory AD. Although 
the reported clinical studies started with a study design ranging from level 2 to 4, the 
resulting evidence levels did not exceed level 4. This was mostly due to the small numbers 
of included patients, which together with the different methodologies of the clinical 
studies forms the main weakness of this review. Presently we need large prospective 
studies to evaluate the efficacy and safety profile of WWT as an intervention treatment in 
children with severe and/or refractory AD. In addition to standardized clinical efficacy and 
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safety parameters, these studies should also include quality of life assessments and cost-
benefit ratios as outcome parameters. These studies are necessary for further 
standardization of the methodology and should focus on the use of diluted topical 
corticosteroids versus emollients and the comparison of WWT with more conventional 
treatment modalities.   
 
Recommendations 
Based on the available data we were able to formulate the following conclusions with 
a grade C of recommendation.  
1. WWT using cream or ointment and a double layer of cotton bandages with a moist 
first layer and a dry second layer, is an efficacious short-term intervention treatment 
in children with severe and/or refractory AD.  
2. The use of wet-wrap dressings with diluted topical corticosteroids is a more 
efficacious short-term intervention treatment in children with severe and/or 
refractory AD than wet-wrap dressings with emollients only.  
3. The use of wet-wrap dressings with diluted topical corticosteroids for up to 14 days is 
a safe intervention treatment in children with severe and/or refractory AD, with 
temporary systemic bioactivity of the corticosteroids as the only reported serious side 
effect. 
4. Lowering the absolute amount of applied topical corticosteroid to once daily 
application and further dilution of the product can reduce the risk of systemic 
bioactivity. 
We would like to stress that the success of WWT depends on adequate training of 
patients and parents in the methodology of the treatment. In our opinion a skilled 
dermatological nurse is invaluable in this process. 
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Background 
The use of dampened bandages to reduce inflamed eczema (synonyme dermatitis) is 
an old remedy. In order to evaluate the current indications for so-called wet-wrap 
treatment (WWT) for atopic dermatitis (AD), and to compare the different currently 
recognized methods, a group of experts critically reviewed their own expertise on WWT in 
respect to the existing literature on the subject. 
 
Results 
WWT is well tolerated in eczema due to the cooling effect on the skin and the rapid 
improvement in skin inflammation. It has been shown to be an extremely effective 
treatment for acute erythrodermic dermatitis, therapy-resistant AD and intolerable 
pruritus. Advantages of WWT include rapid response to therapy, reduction in itch and sleep 
disturbance, and potential for reduction in usage of topical corticosteroids (TCS). 
However, disadvantages include high cost, the necessity for special training in usage, 
potential for increased TCS absorption, increased cutaneous infections and folliculitis, and 
poor tolerability. Precautions to reduce the risks of long-term treatment should include 
education, monitoring of weight and height and, if necessary, serum cortisol levels. In 
adolescents the risk of striae from TCS absorption around puberty is high, and WWT with 
TCS in this age group should be used as a short-term therapy only and with extreme 
caution. To reduce risks, dilutions of steroids may be used ranging from 5 to 10%. In the 
maintenance phase this treatment can be rotated with the use of emollients only. Low 
potency TCS should be used on the face (with a mask). 
 
Conclusion 
WWT using diluted steroids is a relatively safe addition to the therapeutic treatment 
options for children and adults with severe and/or refractory AD. Explanation and 
education is extremely important in the treatment of AD and WWT should only be 
employed by practitioners trained in its use. Specialized nursing care is essential, 
especially when using WWT for prolonged periods. 
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Introduction 
Atopic dermatitis (AD) is an inflammatory, chronically relapsing and pruritic skin 
disease. There is considerable discussion about nomenclature (atopic eczema, atopic 
dermatitis, constitutional eczema, extrinsic and intrinsic atopic dermatitis, atopiform 
eczema and atopic eczema/ dermatitis syndrome) and there is no consensus regarding the 
method for evaluation of the severity of the disease (SCORAD, SASSAD EASI, POEMS, etc.) 
and the role of IgE.1,2 Epidemiological work has shown that the incidence of atopic 
dermatitis is rising in most ‘westernized’ countries although the majority of AD is mild to 
moderate in severity. Only around 10% have a modified objective SCORAD (SCORAD index 
not including subjective symptoms) severity of more than 40, indicating severe AD.3 
Topical corticosteroids (TCS) and emollients are the key players in the therapy of AD. 
Promising drugs such as the calcineurin inhibitors, tacrolimus ointment or pimecrolimus 
cream have recently become available. In severe childhood AD, photo(chemo)therapy, 
systemic corticosteroids and immunosuppressive drugs have relative contraindications 
because of the potential for serious side-effects. These modalities are used only in 
selective cases. For patients with severe AD, agents such as tacrolimus ointment or 
pimecrolimus cream are not efficacious enough in most cases. In children and adults where 
systemic treatment is not appropriate, intermittent treatment with wet wraps (WWT) and 
(diluted) topical corticosteroids and emollients is an ideal option.  
The role of WWT has been a matter of debate over the past 5 years. Wet-wrap 
dressings have been popular in the UK since 1991.4  Earlier use can be dated back to the 
1970s in the UK and even earlier in Australia (M Rogers, Children’s Hospital, Sydney, 
personal communication). In order to evaluate the current indications for WWT, a group of 
experts in paediatric dermatology, with experience of the treatment modality, critically 
reviewed their own experience and the existing literature on the subject. 
 
 
Methods 
Experts in the field of atopic dermatitis in children discussed the therapeutic position 
of wet wraps with diluted steroids and/or emollients in meetings in Malta (2003), 
Rotterdam (2003), Frankfurt (2004) and Budapest (2005). All participants shared their own 
experiences on WWT methods; the use of water (or just emollients), types of dressings and 
bandages and other nursing aspects, choice of TCS and their dilution (or not), and any 
differences in WWT between children and adults. The pros and cons of WWT, indications 
for its use and  precautions to reduce side-effects were considered and compared with the 
experiences found in the literature. 
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Water and dressings 
Wound healing is a complex process influenced by many intrinsic and extrinsic 
factors. From sesame oil used by the Babylonians in 2250 BC and honey used by the 
Egyptians in 2000 BC to the currently available dressings, the evolution of wound products 
has been tremendous. Some factors influencing wound healing have been elucidated, while 
others are still to be discovered. The ancient Babylonians and Egyptians observed that 
covered moist wounds heal more rapidly than open dry wounds, but it took until 1958 for 
Odland to first describe that a blister healed faster when left unbroken.5 Since then many 
studies have demonstrated the beneficial effect of a moist environment on wound 
healing.6  
In a disease such as AD the skin barrier is impaired and significant amounts of water 
are lost through the skin.7  In AD lesional skin a significant decrease in ceramides 1 and 3 
has been found compared with the skin of healthy subjects.8 Non-lesional skin of patients 
with AD also exhibits similar decreases of ceramides, in particular ceramide 1. This may be 
due to the fact that the epidermal enzyme sphingomyelin deacylase is expressed at high 
levels in the epidermis of AD patients, leading to an abnormal accumulation of sphingosyl 
phosphorylcholine but low levels of ceramide.9 However, the biological and genetic 
mechanism behind this high expression remains to be elucidated. A second reason for 
dryness of the skin in AD is the diminished water binding in the stratum corneum due to a 
depletion of hydrophilic molecules such as natural moisturizing factor, probably due to a 
decrease in fillagrin. Finally, sebaceous secretion is also lower than normal in AD patients. 
Sebaceous glands in the dry skin of AD are reduced in number and size compared to those 
in the skin of normal individuals, and the lipids in sebaceous gland secretion are also 
reduced compared to normal subjects.  
The benefit of emollients in AD may be explained by the restoration of the epidermal 
barrier, which prevents the penetration of allergens, irritants and organisms and breaks 
the itch-scratch cycle, thereby reducing the release of inflammatory mediators.10  Wet 
dressings support the rehydration of the skin and afford cooling of the skin through 
evaporation. This gradual cooling has an anti-inflammatory effect and reduces itching. The 
hydration and occlusion provided by the wet wraps also increases the absorption of topical 
medications. These dressings also act as a mechanical barrier against scratching, allowing 
more rapid healing of excoriated lesions and protection against external factors such as 
allergens and bacteria, although heavily infected eczema may be worsened by the 
occlusion.  
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The use of wet dressings in AD generally encompasses a layer of wet tubular cotton 
gauze bandages, of which there are several commercial types available, covered by a 
corresponding layer of dry bandaging. The literature on the appropriate use of water in 
this approach is limited. Advice is usually given to put the bandages in lukewarm water, 
squeeze the water out of the bandages and then apply.11 Nothing is said about the mineral 
content of the water, which may be an important consideration. Recent studies have 
shown that barrier recovery measured by the improvement of transepidermal water loss 
towards normal is inhibited by high extra cellular Ca++ and K+, and accelerated by low 
extracellular concentrations of these ions.12 Another study evaluated the efficacy of cool 
compresses in the treatment of experimentally induced irritant contact dermatitis with 
both distilled water and a physiological salt solution. It was shown that cool compresses of 
distilled water or a physiological salt solution improved barrier function and reduced 
inflammation with no statistical differences between the efficacy of the saline or water 
compresses.13 
The temperature of the water used for wet wraps is also an important factor to 
consider, and the water should be at body temperature. If the water is too cold 
vasoconstriction is soon followed by secondary vasodilation. If too hot, vasodilation occurs 
with increased pruritus. Besides the hardness and the temperature of the water, several 
other mechanisms such as osmolarity and pH may account for the irritancy of water. 
Occlusion per se also changes the physiology of the skin and may trigger the activation of 
potentially active substances.14 
 
Definition of wet-wrap treatment (WWT) 
The use of dampened bandages is commonly used throughout the UK, Hamburg 
(Germany), Munich(Germany), in Rotterdam (Holland) and in several other centres. All 
these treatments are called wet wraps. 
In the 1970s several UK centres used single layer tubular bandages or dampened 
cotton T-shirts and emollients with or without topical corticosteroids (TCS) to control 
widespread AD. An initial report in 1991 of two-layer bandaging wet-wrap therapy (WWT) 
described the use of Tubegauz® impregnated with hydrocortisone cream, with a dry layer 
on top.4 In this “London” method for inpatients no water at all is used. 
Other practitioners in the UK use water-dampened bandages with dry bandages on 
top. This is also the case in the ‘Rotterdam’ method, where the skin is re-wetted every 2 h 
during the day. The skin dries within 30 min and is relatively dry till the next re-wetting 
action (without applying emollients) 90 min later.11,15,16 
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The use of dampened bandages to reduce inflammation is an ancient medical remedy 
and is often used for the treatment of AD. Their use has been described as early as in 
ancient surgical textbooks. In his description of wound dressing, Liston writes in 1846: 
‘water dressings had been applied to sores for time immemorial’. In modified applications 
they continue to be part of approved therapy for acute inflammatory states, ulcers and 
other skin affections.17 
 
 
 
 
Figure 1 
Old style wet wraps (on courtesy of Dr. M. Rogers) 
 
 
 
Details of the four major methods of WWT 
 
Wet wraps (simple) for cooling 
A wet wrap originally consisted of a cloth soaked in water and applied directly to the 
affected skin, usually in several layers. White lint, linen or cotton cloth was formerly used. 
Nowadays a variety of single-use gauze pads are available that can be fixed by a gauze 
bandage to the diseased skin and soaked when required with aqueous liquids. The effect is 
cooling, anti-inflammatory and itch reducing.18 These positive properties of the 
evaporation of water from the dressing are, however, accompanied by a drying out of the 
skin, which makes the procedure theoretically, unsuitable for dry skin conditions like AD. 
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One layer wet wrap with ointment 
To avoid the undesired desiccation of the skin, a modified procedure came into use 
for eczematous conditions, the ‘oil wet wrap’ (‘fett-feuchte Umschläge’). First, an 
ointment is spread generously onto the skin. Then a bandage, soaked in lukewarm tap 
water and squeezed out to leave it damp is applied over it. For extensive skin affections 
damp pyjama cloth can be used instead of bandages. ‘The effect is the same as with wet 
wraps, without the side-effect of drying out the skin’.18 However, ointment enhances the 
risk of folliculitis. 
 
Double-layer wet wrap with ointment or cream and water 
While the damp ‘pyjama’ technique was conceived for in-hospital use, another 
modification more suitable for application at home was described in the nineties19 and 
used in Australia (M Rogers, Children’s Hospital, Sydney, personal communication), 
Dundee, Hamburg, Rotterdam and for out-patients in London (Table 3). A damp tubular 
bandage is applied over the ointment layer, as in the oil-wet wrap, followed by a second 
layer of dry tubular bandage. The second bandage layer results in a more gradual 
evaporation of the water from the wet bandage and therefore in a prolonged effect of 
moisturization and cooling.11,19 
 
   
 
Figure 2      Figure 3 
Tubifast pyjama for WWT.    Preparing for the mask. 
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Double layer wrap with ointment alone 
In 1991, Goodyear et al.4 described another technique for the treatment of AD in 
children, which they termed ‘wet-wrap dressings’. The crucial difference with this method 
is that no water is applied to the bandages. The ‘wetness’ results from diluted steroid 
cream, which becomes more fluid when warmed by immersion in hot water. The bandage 
is soaked in the warm cream and applied to the skin after a bath with oily additive. 
Finally, a second layer of dry tubular bandage is wrapped around.  
 
All of the authors publishing reports on wet-wrap dressings describe a ‘cooling effect 
on the skin’. 4,11,15,16 
 
 
Wet-wrap treatment in children with atopic dermatitis 
The first detailed reports about the use of diluted topical steroids and ‘wet-wrap’ 
dressings in patients with AD were centred on the treatment of children.4,11 They described 
a very successful intervention treatment for severe and/or refractory skin disease with a 
relatively good safety profile. Patients showed a marked improvement of their skin lesions 
associated with a significant decrease in objective SCORAD scores during a clinical 
treatment period of 1 week.15,16 
In the Erasmus MC–Sophia Children’s Hospital (Rotterdam), the treatment is 
commonly started as whole body application and continued throughout a short 
hospitalization of 7 days. After patients have been discharged from the hospital, the 
treatment is continued at home for seven consecutive days on involved areas, and 
thereafter for only 4 days per week (Table 1). Monitoring for potential side-effects is 
undertaken throughout the therapy by measuring fasting early-morning serum cortisol and 
growth parameters. Topical corticosteroids have a well-known potential for systemic and 
local side-effects. Young children are especially at risk for systemic absorption due to their 
low body volume to skin surface area ratio compared to adults. If systemic absorption 
occurs, suppression of the hypothalamus-pituitary-adrenal gland (HPA) axis and growth 
retardation may result. Evaluation of the adverse effects in the published data reveals that 
temporary suppression of the HPA axis has been reported as a possible side-effect of using 
diluted topical steroids and wet-wrap dressings.11,15,16 A local side-effect that may occur 
more easily in childhood than in adulthood is the development of striae, particularly in 
pubertal children (figs 1, 2 and 3). 
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1. 
 
Choose the appropriate width of the tubular bandages and cut these to size to fit the arms, 
legs and trunk. Cut a facial mask if necessary. 
Instead of bandages, tubifast garments are used since 2004. 
2. Apply the appropriate dilution of fluticasone propionate 0,05% (FP) cream on the skin 
Diluted steroids in emollients of 1:19 (face, body in infants) and 1:9 (body) or 1:3 (body) are 
used. 
3. Wet the individual pieces of tubular bandage in lukewarm water. 
When  garments are used, then the inner garment is wetted using a plant spray 
4. Apply the first layer of wet tubular bandage. Connect the arm and leg pieces to the trunk.  
When  garments are used, then the inner garment is wetted using a plant spray 
Use the facial mask if necessary. 
5. Apply the second layer of dry tubular bandage. Again connect the arm and leg pieces to the 
trunk. Use the facial mask if necessary. 
When  garments are used, then a second  dry garment is pulled over the wet one 
6. Re-wet the bandages/ or the inner garments every 2 to 3 hours. 
 
7. Repeat the above mentioned procedures daily. 
 
8. After 7 days of treatment the diluted FP cream is only applied on the clinically involved skin 
for 4 of 7 consecutive days of the week. Emollient is applied on the uninvolved skin. Patients 
can perform the treatment at home. 
 
 
Table 1.  
Wet wraps treatment according to Oranje with recent modification (printed italic) (1999). Since 2004 tubifast 
garments are used. (guidelines Erasmus medical center – Sophia children’s Hospital) 
 
 
 
Using greater dilutions of the topical steroid (1:20 and 1:10) reduces the risk of  
systemic bioactivity, while maintaining a good efficacy.15,16 Fortunately, growth 
retardation as a result of WWT has not been described. This finding is supported by 
McGowan et al., who did not observe any growth retardation in a group of eight children 
during a median period of 12 weeks of WWT.20 They measured velocity of lower leg length 
growth using knemometry, and assessed bone and collagen turnover by urinary 
deoxypyridinoline crosslink excretion corrected for creatinine excretion. However, this is a 
small group, and sensitivity to TCS absorption appears to be very variable. 
In Rotterdam, diluted fluticasone propionate (FP) 0.05% cream (1:4, 1:10 and 1:20) is 
used once daily.15,16 FP cream and mometasone furoate are newer, potent topical 
corticosteroid agents, which have been shown to have an improved benefit/risk ratio with 
relatively low systemic absorption and may further lower the risk of steroidinduced side-
effects. However, there is still a risk of skin atrophy.15,16 Currently, the use of 1:20 
dilutions of FP cream is advocated in children under 2 years of age and dilutions of 1:4 and 
stronger are strongly discouraged. Parameters of systemic bioactivity, such as fasting early 
morning serum cortisol levels should be monitored (i.e. checked before the first day of 
start therapy, after 1, 3, 4, 6 consecutive weeks each and then every 2–3 months). 
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Oranje and coworkers (unpublished data) observed an initial impressive improvement 
after 3 to 7 days, but after 4 weeks worsening and stabilizing of AD to mild to moderate 
severity was observed. We call this the ‘broken stick effect’ (fig. 4). 
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Figure 4 
Double-broken stick phenomenon in objective modified SCORAD evaluation. Retrospective study in 48 children 
with AD treated with wet-wrap dressings with diluted FP cream in the period 2001-2004 (Willems M, Oranje AP, 
unpublished data). 
 
 
 
In Hamburg (department of dermatology) the treatment is as an alternative to 
hospitalization and is conducted in a daycare clinic for 3 to 5 days. Patients are instructed 
by trained nurses to perform double layer wet dressings with the tubular bandage at home, 
using diluted steroid creams only on affected areas and emollients on the rest of the skin 
(B Kunz, personal communication). 
At Great Ormond Street Hospital (GOSH), babies under 1 year of age are treated with 
0.5% hydrocortisone cream and children over 1 year with betamethasone valerate 0.01% 
cream (Betnovate® diluted 1:10) and using Tubegauz bandages. Either aqueous or 
cetomacrogol cream can be used as the diluent (Tables 2 and 3).4 
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ACTION RATIONALE 
Treatment Procedure  
Cut appropriate sized pieces of  the cotton tubular 
bandage [Tubigauz®] for the arms, legs and trunk  
The technique comprises 2 layers of bandaging 
  
Soak the individual pieces of Tubigauz®]  (suit1) in 
the steroid cream 1 (not water)  
To produce the first “wet” layer 
 
Put on the first layer of “wet” Tubigauz®]; tie the 
arm and leg pieces to the trunk  
This enables all affected areas on the limbs and trunk 
to be covered by a dressing impregnated with a weak 
steroid cream 
Then apply the second “dry” suit over the top of 
the wet layer securing the arm and leg pieces to 
the trunk section 
This completes the dressing 
 
Keep hands covered.  If the child is a thumb-sucker 
a small hole can be cut in the bandage. 
To minimise damage from scratching 
 
Treatment regimen  
Dressings are changed twice daily by the nursing 
staff for usually 3 days 
There is usually a rapid improvement and in most cases 
>90% clearance of eczema in this period of time. 
Apply separate topical preparation to face and 
neck as prescribed. 
Areas not covered by the wet dressings 
Treatment immediately after the application of 
wet dressings 
 
The child is kept in hospital for a further one to 
two days and the residual or recurrent areas of 
eczema treated with an appropriate topical steroid 
ointment 2 (without the use of dressings) once or 
twice daily, as needed 
Treatment during this time is then continued after 
discharge from hospital at home. It allows for the skin 
condition to stabilize. 
The use of a moisturizing agent at other times 
during the day to all areas of dry skin (2-3 x daily) 
To maintain the integrity of the skin barrier  
General measures  
Twice daily cool baths with an oily bath emollient To cleanse and hydrate the skin 
Use a soap substitute, such as aqueous cream or 
emulsifying ointment to wash 
Normal soap too drying and can irritate the skin 
If there is any suspicion of secondary bacterial 
infection oral antibiotics should be prescribed by 
the doctor3 
Skin infection may be responsible for the exacerbation 
of eczema 
A sedative antihistamine is also helpful in this 
situation and should be given as prescribed. 
To help settle the child  
 
Loose cotton pyjamas should be worn over wet 
dressings 
To prevent child becoming cold 
Discharge planning  
Educate caregivers on treatment and management 
at home, support with written instructions 
Essential so that the control of eczema is maintained 
 
Liase with GP and community paediatric nursing 
team as appropriate 
To ensure child and care giver supported locally 
Outpatient follow-up appointment within 2 -3 
weeks 
To closely monitor progress and review longterm 
treatment plan 
 
Table 2   
Wet wrap  dressings for in-patient treatment using Tubegauz® (GOSH, London, UK) 
1. Currently we use: for babies under 1yr  0.5% hydrocortisone cream and for children over 1yr 
betamethasone valerate 0.01% cream (Betnovate® diluted 1:10). Both hydrocortisone or Betnovate® can 
be diluted with either aqueous or cetamacragol cream.  
2. Currently we use: for babies under 1yr  1% hydrocortisone ointment and for children over 1yr 
betamethasone valerate 0.025% ointment (Betnovate-RD®) 
3. If there is overt impetiginization then wet dressings should be delayed until 48-72 hours after commencing 
antibiotics and that appropriate treatment has been confirmed from the skin swab results. If eczema 
herpeticum is suspected this is an absolute contraindication to the use of wet dressings.   
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ACTION RATIONALE 
Treatment Procedure  
Apply the weak topical steroid ointment, 
beclomethasone dipropionate 0.0025% 
(Propaderm® 1 in 10) only to the affected areas, 
including the face. 
To reduce inflammation  
Apply 50:50 white soft paraffin/liquid paraffin 
liberally to the unaffected areas 
As a moisturizing agent and to maintain the integrity of 
the skin barrier 
Apply a suit of Tubifast® bandages (one wet layer 
and one dry layer). Tubifast has a tighter fit 
compared to Tubigauz®. The wet layer uses water 
and needs to be kept damp using a sponge or spray 
To reduce itching and prevent damage from scratching; 
as well as maintaining an appropriate skin temperature. 
 
Then apply the second “dry” suit over the top of 
the wet layer securing the arm and leg pieces to 
the trunk section 
This completes the dressing 
 
Treatment regimen  
For use in hospital, dressings are changed twice 
daily for 3 to 5 days 
This will produce a significant improvement sufficient 
for the child to be discharged.  
Continue nightly wet wraps at home for 6-8 weeks 
gradually reducing frequency after this period if 
effective. 
Stopping wet wraps abruptly can induce a flare of 
eczema 
 
 
Table 3   
Wet wrap dressings more suitable for use at home using Tubifast® (Guidelines GOSH, London, UK) 
The initial assessment on admission, general measures and discharge planning are similar to that described 
with the other method (Table 2).  
 
 
In Dundee WWT comprises the use of emollients and one, dampened layer of 
Tubifast® dressings with a dry layer on top. Occasionally, in severe cases, potent or 
moderately potent TCS are used undiluted to affected areas for a maximum of 5 days only. 
Otherwise, and especially in infants, 1% hydrocortisone ointment for 5 to 7 days is applied 
to affected areas only. WWT is only continued on a long-term basis with emollients alone, 
usually at night, and TCS are applied during the day without occlusion to affected areas. In 
a recent Dundee pilot study of 19 infants below 5 years of age with moderate AD, WWT did 
not prove more effective than conventional therapy with 1% topical hydrocortisone cream 
and emollients over a 2-week period.21 
Long-term intermittent treatment with wet-wrap dressings and diluted 
corticosteroids is feasible but requires close monitoring and adequate guidance of patients 
and their parents.16 Regular measurements of fasting early morning serum cortisol and 
growth parameters should be monitored (in long-term treatment at least every 6 to 8 
weeks). For facial eczema, wearing a mask can lead to psychological resistance or 
problems and is refused by about 10% of the parents and/or children22 (A Oranje, personal 
communication). The face is treated with WWT and more diluted steroids (1:20, 5% steroid 
cream) than elsewhere on the skin.23–28 Low-potency steroid without WWT for severe facial 
eczema is also an option. We have now also treated a number of children with 
pimecrolimus 1% cream or tacrolimus 0.03% ointment for facial lesions without occlusion 
by a mask (A Oranje, unpublished data). The effectiveness of topical steroids may diminish 
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with time (tachyphylaxis) and, last but not least, the cost and time-consuming nature of 
the dressings limit their use. 
 
Wet-wrap dressings in adults with refractory atopic dermatitis 
Adult patients with refractory AD unresponsive to topical corticosteroids and 
emollient, photo(chemo)therapy and/or even systemic therapy can be treated with WWT 
using diluted or undiluted steroids. Treatment can be started during a short 
hospitalization, in an outpatient treatment centre, or as an outpatient under the 
supervision of a suitably trained specialist nurse. In a Rotterdam study, after 7 days of 
inpatient therapy with WWT and diluted FP cream (1:4 and 1:10), the WWT was continued 
at home daily (first week). Thereafter for four consecutive days/week (maximum five in 
severe cases), and for a minimum of 12 h each day, diluted FP cream was used once daily 
on clinically involved skin only and emollient alone was used on uninvolved skin. For the 
next 3 days, only emollient was applied.16 The Rotterdam group described results of WWT 
using diluted FP cream (1:4 and 1:10) in seven women and five men, aged between 18 and 
61 years, 3 months (average 29 years and 11 months).16 Two patients were treated using 
the wet-wrap dressings including a facial mask and more diluted steroids (1:20). The 
remaining patients did not use a facial mask at their own request or due to absence of 
facial skin lesions. A marked improvement of skin lesions was noted in all patients.  
One patient using prednisone orally had cortisol levels below 200 nmol/mL both 
before and after treatment. Only two patients developed cortisol levels below 200 
nmol/mL at the end of treatment. Both used additional topical corticosteroids on the face 
and scalp. One patient had been treated with the less diluted and more potent 
concentration of FP cream (1:3) after day 5, and the other one used FP via an inhaler. This 
patient, who used excessive amounts of cream and also FP via an inhaler, developed 
prolonged hypothalamus-pituitary-adrenalcortex (HPA) axis suppression, in combination 
with several striae on his abdomen. 
 
Bandages for use in wet-wrap treatment 
In 1995 a paediatric nursing report described a two-layer technique using tubular 
stretchy bandages Tubifast®, with a wet layer, and dry layer on top, which is widely used 
in a variety of different methods.4,29 This is borne out in a UK review by the British Society 
for Paediatric Dermatology (BSPD), which revealed wide variation in the use of emollients, 
water, TCS  potency and dilution, and bandaging techniques. Some respondents considered 
cream impregnated cotton bandages to constitute WWT and some used a dry bandage 
technique. Recently, a number of new bandages and garments have become available. In 
“Wet-wrap” treatment in AD: an expert’s opinion 105-134 
the UK and other parts of Europe these are Actifast® (Activa), Comfifast® (Shiloh 
Healthcare), Elastus Tubiquick (Most Active), Zipsocs® and Coverflex® (Hartmann); 
however, there may be variation in trade names and availability in other countries. Most 
bandages can only be washed and re-used a few times and they are difficult to apply, 
requiring a trained nurse and committed parents. Incorrect usage may be ineffective and 
potentially harmful. There are a variety of teaching videos and booklets available for 
parents, children and nurses. Medlock Medical now makes Tubifast® garments for WWT for 
varying age groups. These consist of long-sleeved roll-neck T-shirts and pull-up leggings, 
both with external seams to avoid irritancy. These are much simpler and easier to use and 
last up to 20 washes, which greatly offsets their increased cost.  
Although WWT can be very beneficial for severe AD, reducing itching, improving sleep 
and allowing healing and therefore decreased TCS usage, it does have  disadvantages. 
These include high cost, difficulty or intolerance of use and increased risk of cutaneous 
infections and systemic absorption of steroid.29 The use of special silk clothes may be a 
useful addendum in the treatment of AD; however, these clothes fit less well than 
garments. Antiseptic activities are thought to enhance their usefulness. Coater® pyjamas 
are not suitable for children with AD treated with wet wraps. Coaters are made for the 
prevention of scratching and are especially used for children treated with steroids, 
emollients and tar ointments. In London (UK), Tubegauz® or Tubifast® is used and only 
occasionally other dressings such as pyjamas. 
 
Comparative studies with different steroids 
Apart from a few comparative studies, which have described the use of different 
topical treatments (steroid preparations or a steroid preparation vs. a steroid-free 
preparation) under wet-wrap dressings,23,24 no comparative, methodological, evidence-
based studies have been performed focusing on the technique itself. In order to define 
more clearly the most effective wet-wrap technique(s) in atopic dermatitis patients, such 
RCT studies need to be performed. 
 
Nursing and educational aspects 
Explanation and education is of fundamental importance to ensure compliance 
(adherence) to therapy. This should ideally be carried out by trained specialist 
dermatology nurses, as is the case in some UK centres or in eczema schools, which have 
been set up in Germany, France and Holland. It is vitally important that a nurse trained in 
dermatology (and paediatrics for children) assists the patient in initial demonstration of 
treatment and followup to avoid unnecessary side-effects and to reduce risks. Routine or 
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indiscriminate use of WWT in mild AD, particularly by staff untrained in dermatology, 
should be challenged.25–28 In the group’s experience, the most common reason for failure of 
WWT is non-compliance with the dressings. This is frequently a result of lack of knowledge 
and incorrect training by unskilled nurses or medical practitioners. High cost in terms of 
time and money, side-effects such as infection and folliculitis, child dislike or refusal and 
non-availability of dressings or creams are other important factors. 
 
Other indications for wet-wrap treatment 
Wet-wrap treatment can also be used in conditions other than AD such as: 
• Guttate psoriasis with diluted steroids as crisis intervention.  
• Erythrodermic psoriasis with emollients only. 
• Some cases of pruritic and active urticaria pigmentosa (mastocytosis), with diluted 
steroids over a period of 3–6 months. 
• Lamellar ichthyosis in small babies with emollients only. 
 
Precautions and contraindications 
One aspect of potential concern is systemic absorption and hypothalamic-pituitary-
adrenal axis (HPA) suppression. Concerns regarding possible systemic and topical toxicity 
have limited the use of moderate-potency corticosteroids in children.30 Goodyear et al. 
found that even 5 days of topical hydrocortisone cream and WWT in infants resulted in 
some suppression of the HPA, and proposed caution in the use of TCS under WWT.4 The 
relevance of systemic absorption clearly depends on the amount of topical steroid used, 
the frequency of treatment, and close monitoring if used at home. 
If there is overt impetiginization, then wet dressings should be delayed until 48–72 h 
after commencing antibiotics and confirmation of appropriate treatment by skin swab 
results. If eczema herpeticum is suspected this is an absolute contraindication to the use 
of wet dressings.29 
Other problems encountered especially in home use include time-consuming 
application requiring the cooperation of the child; the frequent occurrence of 
Staphylococcal folliculitis; and the rare complication of Pseudomonas infection in the 
creases. The facial mask sometimes leads to psychological problems. We advise low-
potency steroids to be used in the face. Parents also require careful instruction in the 
early diagnosis of eczema herpeticum. 
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Conclusions 
A consensus on the definition of wet-wrap dressings for the treatment of atopic 
dermatitis (AD) can only be based on evidence and this remains to be further established. 
There are only limited evidence-based data demonstrating that WWT with emollients or 
corticosteroids are an effective therapy modality in severe AD.31 The involved experts all 
agreed that wet-wrap treatment in all its different variations is effective for the treatment 
of severe AD. However, randomized controlled studies (RCT) studies to support this 
statement are currently unavailable. 
It has been known for more than 35 years that wet dressings for a period of 1–3 days 
are highly effective for acute flare-ups of AD. Empirically, the experts concluded that in 
severe AD WWT with TCS is highly effective, and safer if diluted TCS are used. In the 
maintenance phase this treatment can be rotated with the use of emollients only. Common 
side-effects are bacterial folliculitis and chilling. Treatment with antiseptics under wet 
wraps seems to be promising, but only limited data are available.32 The role of explanation 
and education is extremely important in the treatment of AD and cannot be 
overemphasized. Increased time spent with children and parents is in itself beneficial. 
Specialized nursing care is essential in long-term therapy using wet-wrap dressings. The 
use of TCS should be limited to short-term therapy, which may be used intermittently 
when necessary, provided that appropriate growth monitoring, and if necessary serum 
cortisol monitoring, is undertaken. Localized WWT can be used for severely affected body 
sites such as limbs, for example. In older children and adults, cream impregnated tubular 
bandages such as Zipsocs® can also be extremely useful for limbs. During long-term 
treatment, a step-down approach for TCS usage is essential: first week once daily, second 
week once daily only to affected areas, and then tapering off to only 4 days per 
week. WWT masks are better reserved for short-term management and are not always 
tolerated. and in cases where long-term TCS are necessary for the face, treatment with 
one of the newer topical immunomodulators may be beneficial. 
In summary, whichever method is used, the effect of wet dressings can be very  
impressive; they can make the child feel more comfortable by rapidly reducing itching and 
thus improving sleep. Wet-wrap dressings are undoubtedly a valuable tool for the 
treatment of children with severe generalized AD. The use of a less potent dilution of FP 
cream or MF cream/ointment has been shown to be effective and diminishes the risk of 
TCS therapy. However, home use requires adequate training and motivation to ensure good 
compliance and must be carefully monitored, while maintaining good efficacy. A daycare 
centre with dermatologically qualified nurses, with appropriate paediatric training, 
provides an excellent setting for the follow-up of these patients. 
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“Wet-wrap” treatment in children with atopic dermatitis:  
a practical guideline 
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Treatment of children with severe atopic dermatitis (AD) can be especially 
challenging as several possible intervention treatments have (relative) contraindications in 
childhood. In recent years wet-wrap treatment (WWT) has been advocated as a relatively 
safe and efficacious intervention treatment in children with severe and/or refractory AD. 
The goal of this publication is to provide a practical guideline as a starting point for 
clinicians who are interested in using WWT in their own clinical practice. We will address 
several  practical issues surrounding the use of WWT by describing our own experiences 
supplemented with data from the literature.  
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Introduction 
Possible intervention treatments in patients with severe atopic dermatitis (AD) 
consist of photo(chemo)therapy or systemic treatments such as oral corticosteroids, 
cyclosporine or azathioprine. In childhood these interventions all have (relative) 
contraindications, which can make treatment of children with severe AD especially 
challenging. 
In recent years wet-wrap treatment (WWT) has been advocated as a relatively safe 
and efficacious intervention treatment in children with severe and/or refractory AD.1 WWT 
is defined as a treatment modality using a double layer of tubular bandages or gauze, with 
a moist first layer and a dry second layer. Despite this general definition there is still 
considerable variation in the reported methodology of WWT, as was described previously 
by us in a systematic review of the literature.2 Important variables include the topical 
products and bandages used, occlusion time and treatment duration.  
The goal of this publication is to provide a practical guideline as a starting point for 
clinicians who are interested in using WWT in their own clinical practice. We will address 
several  practical issues surrounding the use of WWT by describing our own experiences 
supplemented with data from the literature. The methodology described below is the one 
that has been used over the last years in the Pediatric Dermatology unit of the Erasmus MC 
– Sophia Children’s Hospital in Rotterdam, the Netherlands.3 The treatment protocol is 
summarized in table 1 and will be described in more detail below.  
 
 
 
1. 
 
Choose the appropriate size Tubifast Garments to fit the arms, legs and trunk. Cut a facial 
mask from the appropriate size Tubifast if necessary.  
 
2. Apply the appropriate dilution of fluticasone propionate 0,05% (FP) cream on the skin 
 
3. Wet the individual pieces of tubular bandage in lukewarm water. 
 
4. Apply the first layer of wet tubular bandage. Use the facial mask if necessary. 
 
5. Apply the second layer of dry tubular bandage. Again use the facial mask if necessary. 
 
6. Re-wet the bandages every 2 to 3 hours. Rewetting is stopped during the night 
 
7. Repeat the above mentioned procedures daily. 
 
 
Table 1  
Summarization of the WWT protocol as it is currently used in the Pediatric Dermatology unit of the Erasmus MC 
– Sophia Children’s Hospital in Rotterdam, the Netherlands 
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Patient selection based on severity of atopic dermatitis 
WWT was originally developed as an intervention treatment for children with 
widespread and severe AD.4 Although its use has been spreading, we believe WWT should 
still only be used in this select group of difficult to treat patients. This view is supported 
by recent publications that have stressed that WWT treatment should be reserved as a 
second line treatment and is not to be used as a first line treatment in AD.5,6 In Rotterdam 
we only select patients over the age of 6 months with severe AD as is reflected in an 
objective SCORAD score of 35-45 or more.7 This scoring system combines the extent of the 
skin lesions with the intensity of six clinical features of AD. Next to a lower age threshold 
of 6 months we also maintain an upper age threshold at the start of puberty, which is 
usually around 11 years of age. We consider puberty a relative contraindication for the 
treatment due to the a priori increased risk for striae distensa at this age.  
 
Materials needed in wet-wrap treatment 
In our recent review we found WWT with diluted topical corticosteroids to be more 
effective as a short-term intervention treatment in children with severe and/or refractory 
AD than WWT with emollients alone.2 The most commonly reported topical products are 
10% dilutions of potent topical corticosteroids.2 We personally advocate the use of 
dilutions of fluticasone propionate (FP) or mometasone furoate based on their known 
pharmacological properties.8,9 Our own current product consists of a 10% (1 part : 9 parts) 
dilution of FP 0,05%  cream in petrolatum 20% cetomacrogol cream (9 parts), which is 
compounded by our pharmacist. The concentration of FP cream is decreased to 5% (1 part 
:19 parts) if facial lesions are treated. Alternative treatment options for facial lesions 
without using a facial mask include low potency topical corticosteroids or topical 
calcineurine inhibitors. We currently prefer the last option and use pimecrolimus 1% or 
tacrolimus 0.03% ointment.10 
Any type of close fitting cotton bandages could in theory be used in a WWT. We have 
always used Tubifast elasticised tubular cotton bandage, which is also the most commonly 
reported brand in the literature.2 At the moment we almost always use Tubifast Garments 
, which were introduced onto the market in 2003. This product line includes long sleeved 
shirts, pants, socks and gloves in different pediatric sizes. They are made from similar, 
latex free, material as the original Tubifast and can be washed and reused up to 20 times 
according to the manufacturer. Using the garments facilitates the treatment and saves a 
considerable amount of time during the preparation and application phase of the 
treatment. It also reduces the risk for refractory skin lesions on the areas not covered by 
bandages. If facial lesions are also to be treated in the WWT we use the original Tubifast 
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to make a mask by cutting out holes for the eyes, mouth and nose. One should always keep 
in mind the psychosocial consequences of wearing a mask and the fact that not all children 
and/or parents will accept their application. In our patient population between 10-20% of 
children treated with WWT do not use a mask. Their use should always be discussed 
separately with patients and their parents when WWT is considered.  
 
Methodology of application and (re)wetting. 
Patients may be treated on an in-patient basis or via a day-care unit. If the choice is 
available we believe in-patient treatment is preferable due to the complex and time 
consuming nature of the treatment. Each day starts by bathing the patients for 5-10 
minutes in lukewarm water with additional bathing oil by Balneum Hermal. After briefly 
toweling the children dry the cream is then applied directly on the skin in the direction of 
the hair growth, to avoid occlusion of hair follicles. Subsequently the first layer of Tubifast 
Garments is wetted in lukewarm water and put on the skin after gently squeezing out all 
excess water. This is followed by the application of a second, dry layer of Tubifast 
Garments and then the patients pyjama or clothes. The second dry layer slows down the 
evaporation of water from the first layer and makes wearing clothes on the of the 
bandages more comfortable. The first layer of bandage is rewetted every 2-3 hours by 
peeling back the second, dry layer and spraying lukewarm water with a plant sprayer. 
During the night rewetting is stopped to ensure patients can sleep unobtrusively through 
the night. 
Reported application times of the bandages range from 3 to 24 hours a day.2 Longer 
application times are probably more efficacious, although there is no clear evidence to 
support this. In a hospital setting a 24-hour treatment schedule is feasible and in our 
opinion advisable. This is more difficult when patients are treated on an outpatient basis 
and schedules have to be incorporated into daily life, where shorter application times are 
often preferable.  
 
Treatment duration 
WWT interventions of 2 to 14 days have been published in clinical studies.2 When  
diluted topical corticosteroids are used we would like to advocate an intervention 
treatment of 7 days,  with a possible extension to a maximum of 14 days in severe cases. A 
standardized period of 7 days is consistent with the study of Wolkerstorfer et al, who 
reported substantial improvement during the first week of treatment with little further 
improvement in the second week.11 Other authors have also described good clinical 
efficacy with limited treatment periods of up to 1 week.1,2 
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In very severe and recalcitrant cases one can try to use WWT for a prolonged 
maintenance phase by tapering off the frequency off applications. We have personal 
experience with using once daily applications for a maximum of 4-5 consecutive days in the 
week.12 During the remaining days of the week patients are only allowed to use emollients. 
Evidence for this approach is lacking and we have had variable results. In general the 
results during a prolonged maintenance phase as described above seem to be less 
impressive than during a short term intervention.  
 
Safety and possible adverse events 
The use of wet-wrap dressings with diluted topical corticosteroids for up to 14 days is 
a safe intervention treatment in children with severe and/or refractory AD.2 Reported 
adverse events are not common and usually mild and temporary in nature. Transient 
systemic absorption of the topical corticosteroids, resulting in temporary early morning 
fasting serum cortisol levels below the detecting threshold,  is the only reported serious 
side effect.2 Because of this the use of diluted topical corticosteroids should be limited to 
once daily applications. Concomitant use of corticosteroids, for instance via inhalation, 
should be taken into account when starting the treatment. Measurement of early morning 
fasting serum cortisol before and after treatment may be used to asses systemic 
bioactivity. Growth retardation due to WWT treatment has not been reported.1,2,13 
 
 
Adverse event Occurrence 
Discomfort, including chills and poor acceptance  Frequent 
Folliculitis Common 
Refractory skin lesions on areas not covered by bandages Common 
Temporary systemic bioactivity of corticosteroids Common 
Cutaneous Pseudomonas aeruginosa infection Rare 
Impetigo Rare 
Herpetic infections  Rare 
 
Table 2  
Possible adverse events during an intervention treatment with wet-wrap dressings and (diluted) topical 
corticosteroids for a maximum period of 14 days. 
 
Other possible adverse events are listed in table 2. Discomfort is most frequent and 
almost invariably due to chills after application of the first moist layer of bandage. This 
can be reduced by closely monitoring the temperature of the water used. Induction of 
folliculitis is probably due to the occlusive effect of the treatment and may be reduced by 
using creams instead of ointments and application of the topical product in the direction of 
hair growth. This occlusive effect of ointments is the main reason we use a hydrophilic 
cream based emollient like petrolatum 20% cetomacrogol cream as the basis for our topical 
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product. Possible irritants of inflamed skin, like alcohol, propylene glycol or urea should be 
avoided. Secondary skin infections with Pseudomonas aeruginosa appear to be rare, but 
may be linked to the treatment via the moist environment induced by the bandages. 
Insufficient cleaning of the water sprayers used to rewet the first layer of bandages may 
constitute a cause of infection and frequent cleaning of these sprayers is advised. 
Refractory skin lesions on areas not covered by bandages were sometimes seen if solitary 
arm and leg pieces of the bandages were not adequately attached to the central body 
piece. When using the Tubifast Garments this problem does not occur. 
 
 
Figure 1  
Application of the second layer of dry Tubifast Garments on top of the first wetted layer 
 
Whether or not there is an increased risk for other skin infections, such as a bacterial 
impetigo or eczema herpeticum, is still unclear. Both events are well known complications 
in children with AD. However, at the moment there is no data suggesting that they occur 
more frequently during WWT. If these or other secondary skin infections, such as mollusca 
contagiosa or viral warts,  do occur during WWT the treatment should be (temporarily) 
stopped and if possible adequate treatment of the secondary skin infection started.  
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Although striae distensa have not been reported during a wet-wrap intervention 
treatment, they were observed by us during a long-term intermittent treatment in an 
adult.12 Because children entering puberty are already at risk of developing striae, we 
advocate caution at this age and consider it to be a relative contraindication for WWT.   
 
 
 
Figure 2 
Key points to remember 
 
 
Key points 
 
• WWT with diluted topical corticosteroids is an effective and relatively 
safe short term intervention treatment in children with severe AD. 
 
• WWT with diluted topical corticosteroids should only be used as a 
second line, short term intervention treatment in children with AD. 
  
• WWT with diluted corticosteroids is not to be used in children younger 
than 6 months of age or in puberty 
 
• Topical diluted corticosteroids should only be applied once daily when 
used in a WWT. 
 
• Possible adverse events of WWT with diluted topical corticosteroids 
are usually mild and temporary in nature. 
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General discussion 
Caring for children with severe and/or refractory atopic dermatitis (AD) remains 
challenging for both medical practitioners and caregivers. The diagnostic work-up as well 
as disease management differs markedly from that in patients with mild or moderate 
disease, although certain basic aspects remain the same. A desire to improve our daily 
clinical practice for these patients formed the basis for the studies outlined in this thesis. 
 
The first study was aimed at improving our allergologic work-up in young children 
with AD by evaluating the use of the Atopy Patch Test (APT) with food allergens in patients 
aged 0-3 years. Next to our current diagnostic protocol for the diagnosis of a clinically 
relevant food allergy in this patient group, we found the additional value of the APT to be 
very limited at best. The results do not justify the time consuming nature of the skin test 
in our daily clinical practice and we currently advocate using it for research purposes only. 
In a second study we evaluated the characteristics of the APT with aeroallergens in the 
same patient population. We found a substantial number of clear-cut positive APT 
reactions with house dust mite, cat- and dog dander, with a relatively high percentage of 
urticarial reactions. As there is no gold standard for the diagnosis of a relevant allergy to 
aeroallergens in patients with AD, we did not attempt any conclusions with regard to the 
clinical relevance of these positive reactions. We believe further studies with the APT are 
worthwhile to undertake because it does function as an allergen specific delayed type 
hypersensitivity reaction, which still seems promising for future use as a diagnostic or 
prognostic test.   
 
In the second part of this thesis we evaluated plasma matrix metalloproteinase 
(MMP)-9 as a possible objective laboratory marker for the assessment of disease severity in 
AD. Assessment of disease severity is essential in monitoring efficacy of therapeutic 
interventions, both in daily clinical practice as well as in clinical trails. Our results showed 
significantly increased levels of plasma MMP-9 in patients with AD compared to healthy 
controls, suggesting a role for MMP-9 in the pathogenesis of AD. However, disease 
specificity remains questionable and we could not find a significant correlation between 
plasma MMP-9 and the objective SCORAD or TIS as clinical markers of disease severity. 
Larger studies are needed to evaluate plasma MMP-9 levels in AD, including stratification 
for concomitant asthma and allergic rhinitis. 
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The publications on wet-wrap treatment (WWT) with diluted corticosteroids in the 
last section of this thesis substantiate the use of this treatment modality as an effective 
and relatively safe intervention treatment in young children with AD. However, caution is 
still warranted and we believe it should be reserved as a second line treatment in patients 
with severe or refractory skin disease. Long term treatment seems feasible, but adequate 
instruction and a careful follow-up are essential. Larger prospective studies are needed to 
further evaluate the efficacy and safety profile of WWT in AD. Next to standardized 
clinical efficacy and safety parameters, these studies should also include quality of life 
assessments and cost-benefit ratios as outcome parameters. 
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Summary 
The general introduction in chapter 1 provides an overview on atopic dermatitis 
(AD), as a relatively common inflammatory skin disease with a predominance in infancy 
and early childhood. The clinical care for patients with severe and/or refractory AD differs 
from that in patients with mild and moderate disease, especially with regards to diagnostic 
work-up and management. This forms the basis of this thesis, for which the aims are 
described in chapter 2. 
 
The studies in chapter 3 are centred around the possible role of the Atopy Patch 
Test (APT) in the diagnostic work-up of paediatric patients with AD. The APT is a skin test 
aimed at detecting delayed type, eczematous reactions to food and aero-allergens 
commonly associated with direct type, IgE mediated reactions. The chapter starts of with 
an European multicenter study our research-group participated in. This study was initiated 
to define appropriate APT methodology, safety aspects and the relationship between the 
APT and the clinical history of eczema flares. It was added to this thesis with kind 
permission of first author Ulf Darsow. After the inclusion for this study was completed we 
continued with our own studies detailed in the other two publications in this chapter.  
The first study was designed to evaluate the additional value of the APT within our 
own diagnostic protocol for the diagnosis of a relevant food allergy in children below the 
age of 3 years with AD. The results showed clinically relevant food allergies in 23% (egg 
white) to 28% (cow’s milk and peanut) of our patient population. The additional value of 
the APT for reaching this diagnosis was not statistically significant for cow’s milk and egg 
white, but was statistically significant for peanut. However, this statistically significant 
value does not exclude the need for oral challenges as there were false negative as well as 
false positive APT results. 
The second study was aimed at evaluating the APT with aero-allergens in children 
with AD below the age of three years. The presence of positive APT reactions was 
investigated, including their correlation with serum specific IgE and/or the presence of 
positive skin prick tests (SPT). We found a substantial number of clear-cut positive APT 
reactions to house dust mite, cat- and dog dander in our pediatric patient population, with 
a relatively high percentage of urticarial reactions. There was a statistically significant 
agreement between the APT and serum specific IgE as well as the SPT, although the 
strength of agreement was only fair to moderate. As there is no gold standard for the 
diagnosis of a relevant allergy to aeroallergens in patients with AD, we did not attempt any 
conclusions with regard to the clinical relevance of the positive APT reactions. 
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The study described in chapter 4 was initiated to evaluate the presence of plasma 
Matrix metalloproteinase (MMP)-9 in patients with AD as compared to healthy controls, 
including the possible correlation between plasma MMP-9 and disease severity. The MMP’s 
form a group of enzymes, which are capable of hydrolysing protein structures in the extra-
cellular matrix of tissues, thus playing a role in invasive tumour growth, tissue remodelling 
and infiltration of inflammatory cells in tissues. Through cleavage they also play a role in 
shedding of cell membrane associated proteins and activation of pro-enzymes, thus being 
integrated in the inter-cellular signalling pathways. Our results showed significantly 
increased levels of MMP-9 in plasma of patients with AD as compared to healthy controls, 
suggesting a role for MMP-9 in the pathogenesis of AD. However, we could not find a 
significant correlation between plasma MMP-9 levels and the objective SCORAD or Three 
Item Severity score (TIS), as markers of disease severity. 
 
The publications in chapter 5 were initiated to further substantiate and optimize 
wet-wrap treatment (WWT) with diluted topical corticosteroids as an intervention 
treatment for patients with severe and/or refractory AD. This treatment modality 
combines daily application of diluted topical corticosteroids with a moist first layer of 
cotton bandages, followed by a second dry layer.  
The first publication in this chapter describes a retrospective study on the use of a 
standardized WWT protocol in patients with severe and/or refractory AD. Fourteen 
children and 12 adults were treated, using a left-right comparison between different 
dilutions of fluticason propionate 0,05% (FP) cream. After one week of once daily 
applications on the entire skin, a long term treatment was initiated, limiting the diluted 
corticosteroid to eczematous skin areas for only four consecutive days each week. The 
results showed that WWT with diluted corticosteroids, as described above, is a very 
effective intervention treatment. The most important side effect consisted of a 
(temporary) suppression of the HPA-axis in a minority of the patients. The use of a less 
potent dilution of FP cream diminishes this risk, while maintaining a good efficacy. Long-
term treatment at home is feasible when patients (and parents) are motivated and 
provided with adequate instruction and guidance.  
The second publication describes a critical review of the available literature on the 
WWT as an intervention treatment in children with severe and/or refractory AD. The 
different publications were evaluated using the guidelines from the National Health 
Service (NHS) Centre for Reviews and Dissemination of the University of York. Based on the 
available data we were able to formulate the following conclusions with a grade C of 
recommendation.  
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1. WWT using cream or ointment and a double layer of cotton bandages with a moist 
first layer and a dry second layer, is an efficacious short-term intervention treatment 
in children with severe and/or refractory AD.  
2. The use of wet-wrap dressings with diluted topical corticosteroids is a more 
efficacious short-term intervention treatment in children with severe and/or 
refractory AD than wet-wrap dressings with emollients only.  
3. The use of wet-wrap dressings with diluted topical corticosteroids for up to 14 days is 
a safe intervention treatment in children with severe and/or refractory AD, with 
temporary systemic bioactivity of the corticosteroids as the only reported serious side 
effect. 
4. Lowering the absolute amount of applied topical corticosteroid to once daily 
application and further dilution of the product can reduce the risk of systemic 
bioactivity. 
 
The third publication reflects the combined knowledge of a panel of experts on the 
treatment of patients with AD using wet-wrap dressings with diluted corticosteroids and/or 
emollients. They met on four separate occasions, sharing their experiences on the 
methodology, (contra-)indications, efficacy and safety. The conclusions they reached were 
that WWT using diluted corticosteroids is a relatively safe addition to the therapeutic 
treatment options for children and adults with severe and/or refractory AD. Instruction is 
extremely important and WWT should only be employed by practitioners trained in its use. 
Specialized nursing care is essential, especially when using WWT for prolonged periods. 
The goal of the fourth publication was to provide a guideline as a starting point for 
clinicians who are interested in using WWT in their own clinical practice. Several  practical 
issues surrounding the use of WWT are addressed by describing our own experiences 
supplemented with data from the literature.  
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Dankwoord 
Als het einde van een promotietraject begint te naderen ga je vanzelf nadenken over 
het schrijven van een dankwoord voor alle mensen die direct of indirect een bijdrage 
hebben geleverd aan het tot stand komen van het boekje. Uiteindelijk zijn dat er nogal 
wat en is het haast ondoenlijk om ze hier allemaal te noemen. Toch volgt hieronder een 
poging met bij voorbaat mijn excuses aan diegenen die ik vergeten ben. Ook jullie bijdrage 
werd zonder meer gewaardeerd. 
 
Als eerste horen hier natuurlijk mijn promoter, Prof. Dr. A.P. Oranje, en mijn co-
promotor, Dr. F.B. de Waard-van der Spek, genoemd te worden. Best Arnold, zonder jouw 
volhardende en inspirerende begeleiding was dit boekje waarschijnlijk nooit tot stand 
gekomen. Zo lang als ik je ken hebben jouw enorme klinische kennis, je bijna bodemloze 
energie en bovenal je geweldige enthousiasme voor je vak grote indruk op mij gemaakt. 
Dat ik uiteindelijk zelf ook de dermatologie in ben gegaan is grotendeels terug te voeren 
op het plezier waarmee ik gedurende die eerste jaren op de polikliniek kinderdermatologie 
heb gewerkt. Beste Flora, jouw vakkundigheid en de gestructureerde manier waarop je 
werkt zijn voor een beginnend arts en onderzoeker een prachtig referentiekader om zich 
aan vast te houden. Ik heb in de loop van de jaren veel van je geleerd en altijd met veel 
plezier met je samengewerkt.  
Verder zijn ook de volgende mensen heel direct betrokken geweest bij het tot stand 
komen van dit proefschrift. Allereerst de deelnemers, die bij het uitvoeren van elke 
klinische studie onontbeerlijk zijn. Dit proefschrift is volledig gebaseerd op jullie 
medewerking waarvoor mijn dank. Ook de leden van het internationale expert panel dat 
meerdere malen bijeen is gekomen om tot een gemeenschappelijk standpunt over de wet-
wrap behandeling te komen, wil ik hiervoor hartelijk bedanken. Het laboratorium 
Allergologie van het Erasmus MC, onder leiding van Dr. A.W. van Toorenenbergen,  was 
verantwoordelijk voor het leeuwendeel van de laboratorium bepalingen in dit proefschrift. 
Beste Albert, dankbaar heb ik gebruik gemaakt van jouw kennis en de mogelijkheden die 
je mij hebt geboden. Via jou wil ik graag ook de overige medewerkers van het 
laboratorium bedanken voor hun hulp. Voor de statistische analyses in dit proefschrift heb 
ik zwaar op Dr. P.G.H. Mulder geleund. Beste Paul, mijn kennis over biostatistiek werd 
tijdens bezoeken aan jouw kamer iedere keer weer flink opgeschroefd. Helaas blijkt deze 
kennis tijdens lange afwezigheid van jouw kamer ook weer langzaam af te kavelen, waar ik 
voor de toekomst nog iets op moet gaan verzinnen. De promotie commissie heeft 
uiteindelijk het resultaat van mijn inspanningen kritisch beoordeeld waarvoor ik de leden 
graag wil bedanken.  
Acknowledgements  130-134    
Een groot aantal mensen zijn meer indirect bij mijn promotie traject betrokken 
geweest. De start van vond plaats op de afdeling Dermatologie en Venerologie van het 
Erasmus MC, waar ik met veel stafleden, arts-assistenten en overige medewerkers zeer 
plezierig heb samengewerkt. Een aantal namen uit die tijd wil ik toch nog even apart 
noemen: Albert Wolkerstorfer voor het gespreide bedje waar ik als onderzoeksarts in 
terecht kwam, Tim van Meurs voor het bijspringen in de tijd dat we samen op de 
polikliniek kinderdermatologie en de dagbehandeling zaten en Rachel Bakkum en Eric van 
der Snoek voor de vele gezellige lunches aan de “warme kant” van het restaurant. De 
afronding van mijn promotietraject vond plaats terwijl ik als dermatoloog werkzaam was 
binnen de maatschap Dermatologie van het Medisch Centrum Rijmond Zuid, tegenwoordig 
beter bekend als het Maasstad Ziekenhuis. Hier werk ik nog steeds met veel plezier, met 
dank aan mijn directe collega´s, Carmen Hendriks-Iserief, Kokkie Tio en Tim van Meurs, 
maar zeker ook mijn oud collega Babs van Hussen-Brok en alle andere medewerkers van 
onze twee poliklinieken. 
 
Om dit dankwoord af te ronden zijn er nog een aantal mensen uit mijn privé-leven 
die hier niet mogen ontbreken. Allereerst mijn buurmeisje, Jorien Willemse, die 
verantwoordelijk is voor de mooie tekening die de basis vormde van de kaft van dit boekje. 
Verder ook Erik van Driel en Jacques van Splunder, die mij als paranymfen tijdens de 
verdediging met raad en daad zullen bijstaan. Daarnaast mijn ouders, Corry en Toine 
Devillers, die met hun liefde, vertrouwen en wijsheid aan de basis staan van alles wat ik in 
mijn leven heb gepresteerd. Daar kun je volgens mij nooit te vaak dank je wel voor 
zeggen. En dan als laatste natuurlijk mijn echtgenote Marloes, waar ik al vele jaren lief en 
leed mee deel. In de loop van de tijd heb jij zowel mijn geklaag als mijn enthousiasme 
over dit proefschrift moeten aanhoren. We hebben het zo af en toe wel eens samen zitten 
vervloeken, maar nu is het dan toch uiteindelijk af! 
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De schrijver van dit proefschrift werd op 18 april 1974 geboren in Roosendaal. Het 
gezin verhuisde kort na zijn geboorte naar Oud-Beijerland, waar hij in 1992 zijn VWO 
eindexamen behaalde aan de plaatselijke Regionale Scholengemeenschap. Hierna volgde 
de studie Geneeskunde aan de Erasmus Universiteit te Rotterdam, waar hij in 1996 zijn 
doctoraal examen behaalde. Zijn afstudeeronderzoek vond plaats op de polikliniek 
kinderdermatologie van het Erasmus MC - Sophia Kinderziekenhuis en was getiteld 
“congenitale hypotrichosen”. Na het doorlopen van de verschillende co-schappen behaalde 
hij in 1999 zijn artsexamen, waarna hij als onderzoeksarts ging werken op de afdeling 
Dermatologie en Venereologie van het Erasmus MC. In 2001 begon hij hier aan de opleiding 
tot dermatoloog welke hij in mei 2005 volbracht. Sindsdien is hij als dermatoloog 
werkzaam in het Maasstad Ziekenhuis te Rotterdam, met als aandachtsgebied de 
kinderdermatologie. Als vakgerelateerde nevenfuncties is hij momenteel werkzaam als 
bestuurslid van de Vereniging voor Kinderdermatologie, secretaris van het organiserend 
comité van de jaarlijkse cursus “Diagnostiek en Therapie in de Kinderdermatologie” en lid 
van de domeingroep “Eczeem en Allergie” van de Nederlandse Vereniging voor 
Dermatologie en Venereologie. 
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